ketamine has been researched along with Anxiety in 138 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Post hoc data support efficacy of esketamine plus an oral antidepressant in patients with TRD, regardless of comorbid anxiety." | 9.41 | The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. ( Borentain, S; Daly, EJ; Fedgchin, M; Ionescu, DF; Salvadore, G; Singh, JB; Starr, HL; Thase, ME; Trivedi, MH; Turkoz, I, 2021) |
| "The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder." | 9.24 | Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017) |
| "Patients receiving ketamine for refractory depression and anxiety report dissociative symptoms in the first 60 min post-dose." | 9.24 | Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders. ( Castle, C; Glue, P; Gray, A; Neehoff, S, 2017) |
| " Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder." | 9.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| "To compare the effects of intranasal midazolam versus different doses of intranasal ketamine on reducing preoperative pediatric anxiety." | 9.16 | Comparison of the effects of intranasal midazolam versus different doses of intranasal ketamine on reducing preoperative pediatric anxiety: a prospective randomized clinical trial. ( Adeli, N; Hosseini Jahromi, SA; Hosseini Valami, SM; Yazdi, Z, 2012) |
| "To compare the effect of low-dose ketamine with that of low-dose fentanyl on patient anxiety during the identification of the epidural space and catheterization." | 9.09 | Patient anxiety scores after low-dose ketamine or fentanyl for epidural catheter placement. ( Dohi, S; Iida, H; Oda, A, 2000) |
| " The ketamine challenge study in schizophrenia subjects is at the vortex of the current debate." | 9.09 | The schizophrenia ketamine challenge study debate. ( Carpenter, WT, 1999) |
| "Ketamine intravenous therapy (KIT) appears effective for treating depression in controlled trials testing a short series of infusions." | 8.31 | The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis. ( Heifets, BD; Hietamies, TM; Klise, AJ; Levine, SP; McInnes, LA; Qian, JJ; Williams, LM; Worley, MJ, 2023) |
| "Ketamine is a dissociative anesthetic that has been shown to have antidepressant effects in humans and has been proposed as a potential treatment for mood disorders such as posttraumatic stress disorder and aggression." | 8.31 | A single dose of ketamine enhances early life stress-induced aggression with no effect on fear memory, anxiety-like behavior, or depression-like behavior in mice. ( Aaflaq, S; Bartsch, CJ; Jacobs, JT; Li, Z; Nordman, JC; Qasem, E; Skinner, S; Smith, M; Summa, F; Thompson, R, 2023) |
| "One hundred thirty-five Chinese individuals with anxious depression (n = 92) and nonanxious depression (n = 43) received six intravenous infusions of ketamine (0." | 8.12 | Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression. ( Gu, LM; Ning, YP; Tan, JQ; Wang, CY; Yang, XH; Zheng, W; Zhou, YL, 2022) |
| "Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics." | 8.12 | Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study. ( Ahuja, S; Brendle, M; Moore, C; Robison, R; Smart, L; Thielking, P, 2022) |
| " The treatments with ketamine, guanosine, and ketamine plus guanosine were effective to counteract corticosterone-induced anxiety-like phenotype, but not disturbances in the hippocampal NLRP3 pathway." | 8.02 | Low doses of ketamine and guanosine abrogate corticosterone-induced anxiety-related behavior, but not disturbances in the hippocampal NLRP3 inflammasome pathway. ( Camargo, A; Dalmagro, AP; Fraga, DB; Kaster, MP; Rodrigues, ALS; Rosa, JM; Zeni, ALB, 2021) |
| "The aim of this study was to examine the effect on depressive symptoms of repeated subanesthetic doses of SC esketamine in unipolar and bipolar treatment-resistant depression (TRD) and clinical predictors of response." | 8.02 | Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. ( Abdo, G; B Andreoli, S; B Puertas, C; Barbosa, M; Cohrs, FM; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VA; Lacerda, AL; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA, 2021) |
| "Patients with TRD and prominent anxiety receiving IV ketamine exhibited a significant reduction in depressive, SI and anxiety symptoms." | 8.02 | The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. ( Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LM; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, K, 2021) |
| "Ketamine has rapid anxiolytic effects in treatment-resistant obsessive compulsive, post-traumatic stress, generalised anxiety and social anxiety disorders." | 8.02 | Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. ( Glue, P; Gray, A; Neehoff, S; Nehoff, H; Truppman Lattie, D, 2021) |
| "Comparison of the S-ketamine group (n = 8; 4 male, 4 female; average age 52 years) with the control group (n = 8; 3 male, 5 female; average age 55 years) revealed a significant multivariate effect on anxiety and depression F(1, 14) = 4." | 7.96 | A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: a retrospective pilot study. ( Cordes, J; Falk, E; Grau, I; Kienbaum, P; Lutterbeck, MJ; Neukirchen, M; Schlieper, D; Schwartz, J; van Caster, P, 2020) |
| "To determine the effectiveness of intravenous (IV) ketamine on anxiety, irritability, agitation, and suicidality, in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD)." | 7.96 | The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. ( Cha, DS; Fagiolini, A; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Malhi, GS; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Suppes, T; Vinberg, M, 2020) |
| "Here we show that mice prenatally exposed to ketamine displayed anxiety-like behaviors during adulthood, but not during puberty." | 7.96 | Prenatal Exposure to Ketamine Leads to Anxiety-Like Behaviors and Dysfunction in Bed Nucleus of Stria Terminalis. ( Chen, Y; Feng, X; Guo, H; Hu, Y; Li, Y; Lin, J; Lin, L; Liu, T; Lu, Z; Sun, J; Xu, S, 2020) |
| "There is scarce information regarding the effects of anesthetic doses of the non-competitive N-methyl-D-aspartate receptor antagonist ketamine on anxiety." | 7.91 | Effects of Anesthetic Ketamine on Anxiety-Like Behaviour in Rats. ( Antoniou, K; Delis, F; Georgiadou, G; Pitsikas, N, 2019) |
| "Ketamine may achieve its effects on treatment-resistant generalized anxiety disorder and social anxiety disorder through related mechanisms to the common reduction by conventional anxiolytic drugs in right frontal theta." | 7.88 | Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalized Anxiety and Social Anxiety. ( Glue, P; Kawe, T; Martin, D; McNaughton, N; Neehoff, S; Shadli, SM, 2018) |
| "The present study characterized the effects of ketamine on sexual behavior and anxiety in female rats." | 7.88 | The effects of ketamine on sexual behavior, anxiety, and locomotion in female rats. ( Abdel-Rahim, H; Boyette-Davis, J; DeVore, J; Gonzalez, CMF; Guarraci, FA; Kunkel, MN; Lucero, D; Quadlander, E; Stinnett, M; Womble, PD, 2018) |
| "This study tested the effects of ketamine on vulnerability of female adolescent mice to activity-based anorexia (ABA)." | 7.88 | Single injection of ketamine during mid-adolescence promotes long-lasting resilience to activity-based anorexia of female mice by increasing food intake and attenuating hyperactivity as well as anxiety-like behavior. ( Aoki, C; Chen, YW; Sherpa, AD, 2018) |
| "We report a case series on the observed effects of low-dose ketamine infusions in 4 critically ill patients with varying complications related to prolonged critical illness." | 7.83 | Low-Dose Ketamine in Chronic Critical Illness. ( Darrah, D; Moitra, A; Moitra, VK; Patel, MK; Wunsch, H, 2016) |
| " Here, two cases are reported in which a single oral dose of ketamine provided rapid and moderately sustained symptom relief for both depression and anxiety." | 7.76 | Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. ( Iglewicz, A; Irwin, SA, 2010) |
| "It was investigated whether subchronic application of 30 mg/kg ketamine (Ket) induces reliable changes in behaviour and parameters of dopaminergic, glutamatergic, and serotonergic neurotransmissions, which might be the basis of an animal model in schizophrenia research." | 7.72 | Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. ( Becker, A; Grecksch, G; Huether, G; Mann, T; Peters, B; Schroeder, H, 2003) |
| "The aim of the present study was to determine the involvement of the median raphe serotonergic system in the effects of ketamine on anxiety behaviours and related memory." | 7.71 | Effects of ketamine on different types of anxiety/fear and related memory in rats with lesions of the median raphe nucleus. ( Akman, H; Babar, E; Melik, E; Ozgünen, T; Polat, S, 2001) |
| " Demographics, adverse events, and patient-reported dissociation were also analyzed." | 7.11 | At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. ( Akiki, TJ; Arden, K; Gazzaley, A; Hull, TD; Klotz, M; Madan, A; Malgaroli, M; Paleos, C; Swain, J; Vando, L, 2022) |
| "About 20 to 30 percent of patients with Major Depressive Disorder (MDD) do not respond to standard treatment and are considered treatment-resistant." | 6.90 | Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. ( Aust, S; Bajbouj, M; Basso, L; Chae, WR; Cosma, NC; Gärtner, M; Grimm, S; Heuser-Collier, I; Otte, C; Regen, F; van Hall, F; Wingenfeld, K, 2019) |
| "Ketamine is a noncompetitive antagonist of the N-methyl-d-aspartate (NMDA) glutamate receptor, which underlies its induction of pain relief and anaesthesia." | 6.82 | Ketamine treatment for refractory anxiety: A systematic review. ( Brooks, S; Dahlén, AD; Haggarty, CJ; Schiöth, HB; Tully, JL, 2022) |
| "Patients with major depressive disorder often have limited response to first-line and second-line medications; hence, novel pharmacological treatments are needed for treatment-resistant depression (TRD)." | 6.72 | The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et ( Beaulieu, S; Blier, J; Blier, P; Brietzke, E; Frey, BN; Kennedy, SH; Lam, RW; McGirr, A; McIntyre, RS; Milev, RV; Parikh, SV; Ravindran, AV; Ravindran, N; Richard-Devantoy, S; Schaffer, A; Swainson, J; Taylor, VH; Tourjman, V; van Ameringen, M; Yatham, LN, 2021) |
| " The most common treatment-emergent adverse events associated with ketamine/esketamine are dissociation, anxiety, nausea, increased blood pressure, and headache." | 6.72 | Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. ( Cao, B; Ceban, F; Chau, EH; Gill, H; Ho, RC; Kratiuk, K; Kumar, A; Lee, JG; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Swainson, J, 2021) |
| " The control group and the test groups were comparable with regard to biological data, duration of operation, applied dosage of local anaesthetics and actual anxiety before operation." | 6.68 | [Analgesia-sedation for maxillo-facial surgery with midazolam-pentazocine and miazolam-ketamine. Clinical double-blind study of anxiety, analgesia, sedation and amnesia]. ( Daubländer, M; Dick, W; Lipp, M; Sebastian, M, 1995) |
| "Ketamine is a dissociative anesthetic in human and veterinary clinic, as well as an abuse drug that acts on several neurotransmitter systems." | 5.72 | Ketamine acutely impairs memory consolidation and repeated exposure promotes stereotyped behavior without changing anxiety- and aggression-like parameters in adult zebrafish. ( Franscescon, F; Michelotti, P; Müller, TE; Pereira, ME; Rosemberg, DB, 2022) |
| " The higher ketamine use frequency and dosage were associated with more severe depressive symptoms." | 5.43 | Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users. ( Deng, X; Ding, Y; Fan, N; He, H; Ke, X; Ning, Y; Rosenheck, R; Sun, B; Tang, W; Wang, D; Xu, K; Zhou, C, 2016) |
| "Evidence suggests that clinical markers, such as comorbid anxiety, body weight, and others can assist in predicting response to low-dose ketamine infusion in treatment resistant depression patients." | 5.41 | Using classification and regression tree modelling to investigate treatment response to a single low-dose ketamine infusion: Post hoc pooled analyses of randomized placebo-controlled and open-label trials. ( Bai, YM; Chen, MH; Cheng, CM; Hong, CJ; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2021) |
| "Post hoc data support efficacy of esketamine plus an oral antidepressant in patients with TRD, regardless of comorbid anxiety." | 5.41 | The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. ( Borentain, S; Daly, EJ; Fedgchin, M; Ionescu, DF; Salvadore, G; Singh, JB; Starr, HL; Thase, ME; Trivedi, MH; Turkoz, I, 2021) |
| "Ketamine is a non-competitive N-methyl-D-aspartate receptor antagonist that is Food and Drug Administration-approved in the United States for anesthesia due to its sedative effects with low risk of severe respiratory depression." | 5.39 | Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. ( Bloch, MH; Corlett, PR; Grunschel, BD; Niciu, MJ; Pittenger, C, 2013) |
| "Ketamine post-SE onset treatment prevented neuronal death in all regions assessed." | 5.38 | Ketamine reduces neuronal degeneration and anxiety levels when administered during early life-induced status epilepticus in rats. ( Córdova, SD; de Oliveira, DL; Loss, CM, 2012) |
| "Premedication in children with ketamine is useful to produce mild sedation, decrease anxiety, help the child separation from parents, and provide postoperative pain relief with no or little adverse effects." | 5.34 | Analgo-Sedative Effects of Oral or Nebulized Ketamine in Preschoolers Undergoing Elective Surgery: A Comparative, Randomized, Double-Blind Study. ( Amin, OAI; Kamel, AAF, 2020) |
| "To examine the effect of high baseline anxiety on response to ketamine versus midazolam (active placebo) in treatment-resistant depression (TRD)." | 5.30 | Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. ( Cusin, C; Debattista, C; Fava, M; Flynn, M; Freeman, MP; Hock, RS; Hoeppner, B; Ionescu, DF; Iosifescu, DV; Mathew, SJ; Papakostas, GI; Salloum, NC; Sanacora, G; Trivedi, MH, 2019) |
| "The ketamine group was superior to the conventional group which was superior to the no-treatment group in reducing negative affect experienced during stressful situations." | 5.26 | Ketamine-facilitated induced anxiety therapy and its effect upon clients' reactions to stressful situations. ( Becker, AT; Corssen, G; Sappington, AA; Tavakoli, M, 1979) |
| "The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder." | 5.24 | Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. ( Anderson-Fahey, B; Glue, P; Gray, A; Harland, S; Le Nedelec, M; McNaughton, N; Medlicott, NJ; Neehoff, S, 2017) |
| "Patients receiving ketamine for refractory depression and anxiety report dissociative symptoms in the first 60 min post-dose." | 5.24 | Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders. ( Castle, C; Glue, P; Gray, A; Neehoff, S, 2017) |
| "S-ketamine is approved for treatment-resistant patients with depression and adult patients with suicide behavior." | 5.22 | Neurobiological, behavioral, and cognitive effects of ketamine in adolescents: A review of human and pre-clinical research. ( Acevedo, J; Siegel, JA, 2022) |
| " Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder." | 5.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| "To compare the effects of intranasal midazolam versus different doses of intranasal ketamine on reducing preoperative pediatric anxiety." | 5.16 | Comparison of the effects of intranasal midazolam versus different doses of intranasal ketamine on reducing preoperative pediatric anxiety: a prospective randomized clinical trial. ( Adeli, N; Hosseini Jahromi, SA; Hosseini Valami, SM; Yazdi, Z, 2012) |
| "Midazolam and ketamine are useful for oral premedication in children to allay anxiety." | 5.15 | Low- versus high-dose combination of midazolam-ketamine for oral premedication in children for ophthalmologic surgeries. ( Darlong, V; Garg, R; Pandey, R; Punj, J; Shende, D; Singh, M, 2011) |
| " The ketamine challenge study in schizophrenia subjects is at the vortex of the current debate." | 5.09 | The schizophrenia ketamine challenge study debate. ( Carpenter, WT, 1999) |
| "Our understanding of depression and its treatment has advanced with the advent of ketamine as a rapid-acting antidepressant and the development and refinement of tools capable of selectively altering the activity of populations of neuronal subtypes." | 5.05 | Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions. ( Duman, RS; Hare, BD, 2020) |
| " ketamine; deep brain stimulation) that are reported to be effective in treatment-resistant depression and (iv) a parallel to a known clinical risk factor." | 4.91 | Treatment-resistant depression: are animal models of depression fit for purpose? ( Belzung, C; Willner, P, 2015) |
| "Ketamine intravenous therapy (KIT) appears effective for treating depression in controlled trials testing a short series of infusions." | 4.31 | The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis. ( Heifets, BD; Hietamies, TM; Klise, AJ; Levine, SP; McInnes, LA; Qian, JJ; Williams, LM; Worley, MJ, 2023) |
| "Considering the increasing usage of ketamine as a recreational drug with hallucinogenic properties and also scarce studies about receptor systems responsible for its effects, in the present study we aimed to investigate whether the activation of the ventral hippocampal (VH) CB1 cannabinoid receptors affects the anxiety-like behaviors induced by ketamine." | 4.31 | Activation of ventral hippocampal CB1 receptors inhibits ketamine-induced anxiogenic-like behavior: Alteration of BDNF/c-Fos levels in the mouse hippocampus. ( Alijanpour, S; Rezayof, A, 2023) |
| "Ketamine is an anesthetic drug that has recently been approved for the treatment of treatment-resistant depression." | 4.31 | The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice. ( Acevedo, J; Johnson, EM; Mugarura, NE; Siegel, JA; Welter, AL, 2023) |
| "Ketamine enhances the resilience against stress-induced depressive-like behavior, but its prophylactic efficacy in anxiety-related behaviors remains to be elucidated." | 4.12 | Prophylactic efficacy of ketamine, but not the low-trapping NMDA receptor antagonist AZD6765, against stress-induced maladaptive behavior and 4E-BP1-related synaptic protein synthesis impairment. ( Alves, EC; Camargo, A; Dalmagro, AP; Fraga, DB; Kouba, BR; Rodrigues, ALS; Torrá, ACNC; Valverde, AP, 2022) |
| "One hundred thirty-five Chinese individuals with anxious depression (n = 92) and nonanxious depression (n = 43) received six intravenous infusions of ketamine (0." | 4.12 | Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression. ( Gu, LM; Ning, YP; Tan, JQ; Wang, CY; Yang, XH; Zheng, W; Zhou, YL, 2022) |
| "Ketamine has emerged as a promising pharmacotherapy for depression and other mental illnesses, and the intramuscular (IM) administration of ketamine is now offered at many North American outpatient psychiatric clinics." | 4.12 | Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study. ( Ahuja, S; Brendle, M; Moore, C; Robison, R; Smart, L; Thielking, P, 2022) |
| "The aim of this study was to examine the effect on depressive symptoms of repeated subanesthetic doses of SC esketamine in unipolar and bipolar treatment-resistant depression (TRD) and clinical predictors of response." | 4.02 | Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. ( Abdo, G; B Andreoli, S; B Puertas, C; Barbosa, M; Cohrs, FM; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VA; Lacerda, AL; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA, 2021) |
| " The treatments with ketamine, guanosine, and ketamine plus guanosine were effective to counteract corticosterone-induced anxiety-like phenotype, but not disturbances in the hippocampal NLRP3 pathway." | 4.02 | Low doses of ketamine and guanosine abrogate corticosterone-induced anxiety-related behavior, but not disturbances in the hippocampal NLRP3 inflammasome pathway. ( Camargo, A; Dalmagro, AP; Fraga, DB; Kaster, MP; Rodrigues, ALS; Rosa, JM; Zeni, ALB, 2021) |
| " Ketamine is a unique and safe drug that enables well-controlled sedation and anesthesia, attenuates depression and mitigates suicidal thoughts, without depressing respiratory or cardiovascular mechanics." | 4.02 | Perspectives of Ketamine Use in COVID-19 Patients. ( Weinbroum, AA, 2021) |
| "Patients with TRD and prominent anxiety receiving IV ketamine exhibited a significant reduction in depressive, SI and anxiety symptoms." | 4.02 | The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence. ( Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LM; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, K, 2021) |
| "Ketamine has rapid anxiolytic effects in treatment-resistant obsessive compulsive, post-traumatic stress, generalised anxiety and social anxiety disorders." | 4.02 | Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. ( Glue, P; Gray, A; Neehoff, S; Nehoff, H; Truppman Lattie, D, 2021) |
| " Levels of the three markers did not correlate with ketamine use variables, craving, depression, or anxiety symptoms." | 3.96 | Chronic ketamine abuse is associated with orexin-A reduction and ACTH elevation. ( Chang, HM; Chen, CH; Chen, CK; Chen, LY; Huang, MC; Lin, SK; Xu, K, 2020) |
| "We included 104 patients with KD (76 males and 28 females) who received inpatient treatment for ketamine withdrawal and assessed them by using Beck Depression Inventory (BDI), Beck Anxiety Inventory, and a visual analog scale (VAS; 0-100 mm) for ketamine craving on day 2 to 3 of admission." | 3.96 | Association of Craving and Depressive Symptoms in Ketamine-Dependent Patients Undergoing Withdrawal Treatment. ( Chang, HM; Chen, CH; Chen, CK; Chen, LY; Huang, MC; Xu, K, 2020) |
| "Comparison of the S-ketamine group (n = 8; 4 male, 4 female; average age 52 years) with the control group (n = 8; 3 male, 5 female; average age 55 years) revealed a significant multivariate effect on anxiety and depression F(1, 14) = 4." | 3.96 | A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: a retrospective pilot study. ( Cordes, J; Falk, E; Grau, I; Kienbaum, P; Lutterbeck, MJ; Neukirchen, M; Schlieper, D; Schwartz, J; van Caster, P, 2020) |
| "Here we show that mice prenatally exposed to ketamine displayed anxiety-like behaviors during adulthood, but not during puberty." | 3.96 | Prenatal Exposure to Ketamine Leads to Anxiety-Like Behaviors and Dysfunction in Bed Nucleus of Stria Terminalis. ( Chen, Y; Feng, X; Guo, H; Hu, Y; Li, Y; Lin, J; Lin, L; Liu, T; Lu, Z; Sun, J; Xu, S, 2020) |
| "To determine the effectiveness of intravenous (IV) ketamine on anxiety, irritability, agitation, and suicidality, in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD)." | 3.96 | The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. ( Cha, DS; Fagiolini, A; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lin, K; Lipsitz, O; Malhi, GS; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Suppes, T; Vinberg, M, 2020) |
| "Arc-CreERT2 × CAG-Sun1/sfGFP mice showed sex differences in social and anxiety behavior and a different pattern between ketamine and (2R,6R)-HNK in the FST in male and female mice." | 3.96 | Sexually Dimorphic Behavioral Profile in a Transgenic Model Enabling Targeted Recombination in Active Neurons in Response to Ketamine and (2R,6R)-Hydroxynorketamine Administration. ( Herzog, DP; Lutz, B; Mellema, RM; Müller, MB; Remmers, F; Treccani, G, 2020) |
| " These behavioral effects are associated with i/ a reversal of anxiety and reduced self-care, ii/ a decrease in parenchymal cytokine production, iii/ a modulation of the microglial reactivity and iv/ a decrease in microglial quinolinic acid production that is correlated with plasmatic peripheral production." | 3.91 | Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. ( Abdel-Ahad, P; Blatzer, M; Callebert, J; Chrétien, F; Danckaert, A; de Maricourt, P; De Medeiros, GF; Gaillard, R; Jouvion, G; Langeron, O; Launay, JM; Maignan, A; Petit, AC; Sharshar, T; Van Steenwinckel, J; Verdonk, F; Vinckier, F, 2019) |
| "In this longitudinal study, 114 ketamine users completed clinical and cognitive assessments at both baseline and 12-week follow-up with the following instruments: Severity of Dependence Scale, Beck Depression Inventory (BDI), Anxiety Subscale of the Hospital Anxiety Depression Scale (HADSA), and a cognitive battery." | 3.91 | Recovery of cognitive functioning following abstinence from ketamine. ( Lane, HY; Lau, CG; Lin, SK; Tang, WK; Ungvari, GS, 2019) |
| "Patients with IBS who underwent elective colonoscopy procedures expressed higher pre-procedural anxiety scores, required more propofol consumption, and experienced more disruptive movements compared with controls." | 3.88 | Ambulatory colonoscopy under sedoanalgesia in adult patients with and without irritable bowel syndrome: A prospective, cross-sectional, and double-blind comparison. ( Araz, C; Çelebi, A; Tuncalı, B, 2018) |
| "This study tested the effects of ketamine on vulnerability of female adolescent mice to activity-based anorexia (ABA)." | 3.88 | Single injection of ketamine during mid-adolescence promotes long-lasting resilience to activity-based anorexia of female mice by increasing food intake and attenuating hyperactivity as well as anxiety-like behavior. ( Aoki, C; Chen, YW; Sherpa, AD, 2018) |
| "Ketamine may achieve its effects on treatment-resistant generalized anxiety disorder and social anxiety disorder through related mechanisms to the common reduction by conventional anxiolytic drugs in right frontal theta." | 3.88 | Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalized Anxiety and Social Anxiety. ( Glue, P; Kawe, T; Martin, D; McNaughton, N; Neehoff, S; Shadli, SM, 2018) |
| "This study aimed to test stage- and dose-dependent effects of ketamine exposure on certain brain functions by evaluating alterations in locomotion, anxiety-like and avoidance behaviors, as well as socialization." | 3.85 | Behavioral alterations of zebrafish larvae after early embryonic exposure to ketamine. ( Antunes, LM; Coimbra, AM; Félix, LM; Valentim, AM, 2017) |
| "We report a case series on the observed effects of low-dose ketamine infusions in 4 critically ill patients with varying complications related to prolonged critical illness." | 3.83 | Low-Dose Ketamine in Chronic Critical Illness. ( Darrah, D; Moitra, A; Moitra, VK; Patel, MK; Wunsch, H, 2016) |
| "One of the most striking discoveries in the treatment of major depression was the finding that infusion of a single sub-anesthetic dose of ketamine induces rapid and sustained antidepressant effects in treatment-resistant depressed patients." | 3.83 | Repeated ketamine treatment induces sex-specific behavioral and neurochemical effects in mice. ( Mauch, J; Pandit, R; Pitychoutis, PM; Sens, J; Thelen, C, 2016) |
| "Ketamine (20 mg/kg) reversed the chronic unpredictable stress-induced depression-like behaviors in the FST." | 3.79 | Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats. ( Alcantara, LF; Bolaños-Guzmán, CA; Hadad, R; Iñiguez, SD; Kroeck, KG; Parise, EM; Sial, OK; Warren, BL; Wright, KN, 2013) |
| " Here, two cases are reported in which a single oral dose of ketamine provided rapid and moderately sustained symptom relief for both depression and anxiety." | 3.76 | Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. ( Iglewicz, A; Irwin, SA, 2010) |
| "It was investigated whether subchronic application of 30 mg/kg ketamine (Ket) induces reliable changes in behaviour and parameters of dopaminergic, glutamatergic, and serotonergic neurotransmissions, which might be the basis of an animal model in schizophrenia research." | 3.72 | Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. ( Becker, A; Grecksch, G; Huether, G; Mann, T; Peters, B; Schroeder, H, 2003) |
| " Demographics, adverse events, and patient-reported dissociation were also analyzed." | 3.11 | At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. ( Akiki, TJ; Arden, K; Gazzaley, A; Hull, TD; Klotz, M; Madan, A; Malgaroli, M; Paleos, C; Swain, J; Vando, L, 2022) |
| "About 20 to 30 percent of patients with Major Depressive Disorder (MDD) do not respond to standard treatment and are considered treatment-resistant." | 2.90 | Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. ( Aust, S; Bajbouj, M; Basso, L; Chae, WR; Cosma, NC; Gärtner, M; Grimm, S; Heuser-Collier, I; Otte, C; Regen, F; van Hall, F; Wingenfeld, K, 2019) |
| "Ketamine is a noncompetitive antagonist of the N-methyl-d-aspartate (NMDA) glutamate receptor, which underlies its induction of pain relief and anaesthesia." | 2.82 | Ketamine treatment for refractory anxiety: A systematic review. ( Brooks, S; Dahlén, AD; Haggarty, CJ; Schiöth, HB; Tully, JL, 2022) |
| "The incidence of postoperative pain and vomiting as well as the severity of postoperative pain were compared between study groups during the 6-hour postoperative period using a visual analog scale (VAS) at rest, upon swallowing saliva, drinking liquids and eating ice cream." | 2.76 | Intravenous and peritonsillar infiltration of ketamine for postoperative pain after adenotonsillectomy: a randomized placebo-controlled clinical trial. ( Dehghankhalili, M; Ghaffarpasand, F; Heiran, HR; Khademi, S; Motazedian, S; Yavari, MJ, 2011) |
| "Patients with major depressive disorder often have limited response to first-line and second-line medications; hence, novel pharmacological treatments are needed for treatment-resistant depression (TRD)." | 2.72 | The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et ( Beaulieu, S; Blier, J; Blier, P; Brietzke, E; Frey, BN; Kennedy, SH; Lam, RW; McGirr, A; McIntyre, RS; Milev, RV; Parikh, SV; Ravindran, AV; Ravindran, N; Richard-Devantoy, S; Schaffer, A; Swainson, J; Taylor, VH; Tourjman, V; van Ameringen, M; Yatham, LN, 2021) |
| " The most common treatment-emergent adverse events associated with ketamine/esketamine are dissociation, anxiety, nausea, increased blood pressure, and headache." | 2.72 | Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. ( Cao, B; Ceban, F; Chau, EH; Gill, H; Ho, RC; Kratiuk, K; Kumar, A; Lee, JG; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Swainson, J, 2021) |
| "Nimodipine pretreatment attenuated the perceived similarity of ketamine effects to ethanol as well as ketamine-induced euphoria and sedation." | 2.70 | Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. ( Burakov, AM; Fletcher, J; Grinenko, AY; Grinenko, NI; Krupitsky, EM; Krystal, JH; Petrakis, IL; Romanova, TN, 2001) |
| "001) but times from dosing to discharge (medians 105 and 110 minutes) were similar." | 2.70 | Sedation for children requiring wound repair: a randomised controlled double blind comparison of oral midazolam and oral ketamine. ( Kendall, JM; Younge, PA, 2001) |
| " The control group and the test groups were comparable with regard to biological data, duration of operation, applied dosage of local anaesthetics and actual anxiety before operation." | 2.68 | [Analgesia-sedation for maxillo-facial surgery with midazolam-pentazocine and miazolam-ketamine. Clinical double-blind study of anxiety, analgesia, sedation and amnesia]. ( Daubländer, M; Dick, W; Lipp, M; Sebastian, M, 1995) |
| " The use of MAD even gives as better bioavailability of drugs." | 2.58 | Intranasal drug administration for procedural sedation in children admitted to pediatric Emergency Room. ( Chiaretti, A; Fabrizio, GC; Fantacci, C; Ferrara, P; Franceschi, F, 2018) |
| " It also reviews the comparative pharmacokinetics, adverse effects, and dosing of ketamine, propofol, and ketofol as agents for procedural sedation and analgesia." | 2.48 | Ketamine, propofol, and ketofol use for pediatric sedation. ( Alletag, MJ; Auerbach, MA; Baum, CR, 2012) |
| "Ketamine, which acts as a noncompetitive antagonist of glutamatergic NMDA receptors by binding to the phencyclidine site, may induce schizophrenia-like symptoms and promote anxiogenic-like behaviour." | 1.51 | Comparison of the effects of 1MeTIQ and olanzapine on performance in the elevated plus maze test and monoamine metabolism in the brain after ketamine treatment. ( Antkiewicz-Michaluk, L; Białoń, M; Wąsik, A; Żarnowska, M, 2019) |
| "Ketamine has become increasingly popular in adolescent drug abusers worldwide." | 1.51 | The effects of sub-anesthetic ketamine plus ethanol on behaviors and apoptosis in the prefrontal cortex and hippocampus of adolescent rats. ( Fan, SJ; Jiang, H; Li, Q; Liu, DX; Pan, F; Wu, HR; Zhang, Q, 2019) |
| " The higher ketamine use frequency and dosage were associated with more severe depressive symptoms." | 1.43 | Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users. ( Deng, X; Ding, Y; Fan, N; He, H; Ke, X; Ning, Y; Rosenheck, R; Sun, B; Tang, W; Wang, D; Xu, K; Zhou, C, 2016) |
| "Ketamine (Ketalar®) is a non-competitive glutamatergic antagonist classically used to induce sedation." | 1.42 | Behavioral, endocrine, and neuronal alterations in zebrafish (Danio rerio) following sub-chronic coadministration of fluoxetine and ketamine. ( Hylton, A; Pittman, J, 2015) |
| "Ketamine is an anesthetic with antidepressant properties." | 1.42 | The positive effect on ketamine as a priming adjuvant in antidepressant treatment. ( Dalla, C; Ferreira, C; Kokras, N; Melo, A; Pêgo, JM; Sousa, N; Ventura-Silva, AP, 2015) |
| "Ketamine users are often poly-substance users." | 1.39 | Cognitive impairments in poly-drug ketamine users. ( Chan, F; Lau, CG; Liang, HJ; Tang, A; Tang, WK; Ungvari, GS, 2013) |
| "Ketamine is a non-competitive N-methyl-D-aspartate receptor antagonist that is Food and Drug Administration-approved in the United States for anesthesia due to its sedative effects with low risk of severe respiratory depression." | 1.39 | Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. ( Bloch, MH; Corlett, PR; Grunschel, BD; Niciu, MJ; Pittenger, C, 2013) |
| "Ketamine post-SE onset treatment prevented neuronal death in all regions assessed." | 1.38 | Ketamine reduces neuronal degeneration and anxiety levels when administered during early life-induced status epilepticus in rats. ( Córdova, SD; de Oliveira, DL; Loss, CM, 2012) |
| "Tachycardia was the most common physical examination finding." | 1.31 | Ketamine abusers presenting to the emergency department: a case series. ( Bayer, MJ; McKay, CA; Vieira, L; Weiner, AL, 2000) |
| "The ketamine group was superior to the conventional group which was superior to the no-treatment group in reducing negative affect experienced during stressful situations." | 1.26 | Ketamine-facilitated induced anxiety therapy and its effect upon clients' reactions to stressful situations. ( Becker, AT; Corssen, G; Sappington, AA; Tavakoli, M, 1979) |
| "Fifty-six young and 29 middle-aged adults who were scheduled for lower abdominal, anorectal or extremity surgery under epidural, sacral or brachial plexus blockades received intravenous analgesic or anaesthetic doses of ketamine, combined with diazepam, immediately before the start of the operation." | 1.26 | Untoward effects of ketamine combined with diazepam for supplementing conduction anaesthesia in young and middle-aged adults. ( Korttila, K; Levänen, J, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (9.42) | 18.7374 |
| 1990's | 5 (3.62) | 18.2507 |
| 2000's | 16 (11.59) | 29.6817 |
| 2010's | 60 (43.48) | 24.3611 |
| 2020's | 44 (31.88) | 2.80 |
| Authors | Studies |
|---|---|
| Camargo, A | 2 |
| Torrá, ACNC | 1 |
| Dalmagro, AP | 2 |
| Valverde, AP | 1 |
| Kouba, BR | 1 |
| Fraga, DB | 3 |
| Alves, EC | 1 |
| Rodrigues, ALS | 3 |
| Michelotti, P | 1 |
| Franscescon, F | 1 |
| Müller, TE | 1 |
| Rosemberg, DB | 1 |
| Pereira, ME | 1 |
| Zoladz, PR | 1 |
| Del Valle, CR | 1 |
| Goodman, CS | 1 |
| Dodson, JL | 1 |
| Smith, IF | 1 |
| Elmouhawesse, KM | 1 |
| Sparkman, HR | 1 |
| Naylor, MM | 1 |
| Hopson, EP | 1 |
| Tully, JL | 1 |
| Dahlén, AD | 1 |
| Haggarty, CJ | 1 |
| Schiöth, HB | 1 |
| Brooks, S | 1 |
| Zheng, W | 2 |
| Yang, XH | 1 |
| Gu, LM | 1 |
| Tan, JQ | 1 |
| Zhou, YL | 1 |
| Wang, CY | 1 |
| Ning, YP | 1 |
| Hull, TD | 1 |
| Malgaroli, M | 1 |
| Gazzaley, A | 1 |
| Akiki, TJ | 1 |
| Madan, A | 1 |
| Vando, L | 1 |
| Arden, K | 1 |
| Swain, J | 1 |
| Klotz, M | 1 |
| Paleos, C | 1 |
| Acevedo, J | 3 |
| Siegel, JA | 3 |
| Pałucha-Poniewiera, A | 1 |
| Oliver, PA | 1 |
| Snyder, AD | 1 |
| Feinn, R | 1 |
| Malov, S | 1 |
| McDiarmid, G | 1 |
| Arias, AJ | 1 |
| Ahuja, S | 1 |
| Brendle, M | 1 |
| Smart, L | 1 |
| Moore, C | 1 |
| Thielking, P | 1 |
| Robison, R | 1 |
| Mugarura, NE | 2 |
| Welter, AL | 2 |
| Johnson, EM | 2 |
| Pastuszak, M | 1 |
| Wiglusz, MS | 1 |
| da Silveira, CCM | 1 |
| Cartágenes, SC | 1 |
| Kobayashi, NHC | 1 |
| Farias, SV | 1 |
| de Souza-Junior, FJC | 1 |
| Fernandes, LMP | 1 |
| do Prado, AF | 1 |
| Aragão, WAB | 1 |
| Lima, RR | 1 |
| Ferreira, WAS | 1 |
| de Oliveira, EHC | 1 |
| Mello Júnior, FAR | 1 |
| Burbano, RMR | 1 |
| Fontes-Júnior, EA | 1 |
| Maia, CDSF | 1 |
| Alijanpour, S | 1 |
| Rezayof, A | 1 |
| Subramanian, S | 1 |
| Oughli, HA | 1 |
| Gebara, MA | 1 |
| Palanca, BJA | 1 |
| Lenze, EJ | 1 |
| Hietamies, TM | 1 |
| McInnes, LA | 1 |
| Klise, AJ | 1 |
| Worley, MJ | 1 |
| Qian, JJ | 1 |
| Williams, LM | 1 |
| Heifets, BD | 1 |
| Levine, SP | 1 |
| Bartsch, CJ | 1 |
| Aaflaq, S | 1 |
| Jacobs, JT | 1 |
| Smith, M | 1 |
| Summa, F | 1 |
| Skinner, S | 1 |
| Qasem, E | 1 |
| Thompson, R | 1 |
| Li, Z | 1 |
| Nordman, JC | 1 |
| Chen, Y | 2 |
| Yan, P | 1 |
| Wei, S | 1 |
| Zhu, Y | 1 |
| Lai, J | 1 |
| Zhou, Q | 1 |
| Curpan, AS | 1 |
| Savuca, A | 1 |
| Hritcu, LD | 1 |
| Solcan, C | 1 |
| Nicoara, MN | 1 |
| Luca, AC | 1 |
| Ciobica, AS | 1 |
| Liu, W | 1 |
| Zhou, Y | 1 |
| Wang, C | 2 |
| Zhan, Y | 1 |
| Lan, X | 1 |
| Zhang, B | 1 |
| Li, H | 1 |
| Chen, L | 1 |
| Ning, Y | 2 |
| Wang, W | 2 |
| Zhou, T | 1 |
| Jia, R | 1 |
| Zhang, H | 2 |
| Zhang, Y | 1 |
| Dong, Y | 1 |
| Wang, J | 2 |
| Sheng, L | 1 |
| Wu, H | 1 |
| Chen, G | 1 |
| Xue, W | 1 |
| Tang, WK | 2 |
| Lau, CG | 2 |
| Ungvari, GS | 2 |
| Lin, SK | 2 |
| Lane, HY | 1 |
| Chen, LY | 2 |
| Chen, CK | 2 |
| Chen, CH | 2 |
| Chang, HM | 2 |
| Huang, MC | 2 |
| Xu, K | 3 |
| Wu, C | 1 |
| Wang, Y | 2 |
| He, Y | 1 |
| Wu, S | 1 |
| Xie, Z | 2 |
| Zhang, J | 1 |
| Shen, J | 1 |
| Wang, Z | 1 |
| He, L | 1 |
| Falk, E | 1 |
| Schlieper, D | 1 |
| van Caster, P | 1 |
| Lutterbeck, MJ | 1 |
| Schwartz, J | 1 |
| Cordes, J | 1 |
| Grau, I | 1 |
| Kienbaum, P | 1 |
| Neukirchen, M | 1 |
| Silote, GP | 1 |
| de Oliveira, SFS | 1 |
| Ribeiro, DE | 1 |
| Machado, MS | 1 |
| Andreatini, R | 1 |
| Joca, SRL | 1 |
| Beijamini, V | 1 |
| Sun, J | 1 |
| Lin, J | 1 |
| Feng, X | 1 |
| Lu, Z | 1 |
| Liu, T | 1 |
| Lin, L | 1 |
| Hu, Y | 1 |
| Li, Y | 1 |
| Xu, S | 1 |
| Guo, H | 1 |
| Hare, BD | 1 |
| Duman, RS | 1 |
| Kamel, AAF | 1 |
| Amin, OAI | 1 |
| Herzog, DP | 1 |
| Mellema, RM | 1 |
| Remmers, F | 1 |
| Lutz, B | 1 |
| Müller, MB | 1 |
| Treccani, G | 1 |
| McIntyre, RS | 4 |
| Lipsitz, O | 3 |
| Rodrigues, NB | 3 |
| Lee, Y | 3 |
| Cha, DS | 1 |
| Vinberg, M | 1 |
| Lin, K | 2 |
| Malhi, GS | 1 |
| Subramaniapillai, M | 3 |
| Kratiuk, K | 3 |
| Fagiolini, A | 1 |
| Gill, H | 3 |
| Nasri, F | 3 |
| Mansur, RB | 3 |
| Suppes, T | 1 |
| Ho, R | 2 |
| Rosenblat, JD | 3 |
| Chen, MH | 2 |
| Lin, WC | 2 |
| Wu, HJ | 2 |
| Bai, YM | 2 |
| Li, CT | 2 |
| Tsai, SJ | 2 |
| Hong, CJ | 2 |
| Tu, PC | 2 |
| Cheng, CM | 2 |
| Su, TP | 2 |
| Truppman Lattie, D | 1 |
| Nehoff, H | 1 |
| Neehoff, S | 4 |
| Gray, A | 3 |
| Glue, P | 4 |
| Zhang, X | 1 |
| Kong, Y | 1 |
| He, G | 1 |
| Zhou, Z | 1 |
| Lamanna, J | 1 |
| Isotti, F | 1 |
| Ferro, M | 1 |
| Racchetti, G | 1 |
| Anchora, L | 1 |
| Rucco, D | 1 |
| Malgaroli, A | 1 |
| Munkholm, K | 1 |
| Jørgensen, KJ | 1 |
| Lui, LM | 1 |
| Teopiz, K | 1 |
| Swainson, J | 2 |
| McGirr, A | 1 |
| Blier, P | 1 |
| Brietzke, E | 1 |
| Richard-Devantoy, S | 1 |
| Ravindran, N | 1 |
| Blier, J | 1 |
| Beaulieu, S | 1 |
| Frey, BN | 1 |
| Kennedy, SH | 1 |
| Milev, RV | 1 |
| Parikh, SV | 1 |
| Schaffer, A | 1 |
| Taylor, VH | 1 |
| Tourjman, V | 1 |
| van Ameringen, M | 1 |
| Yatham, LN | 1 |
| Ravindran, AV | 1 |
| Lam, RW | 1 |
| Lucchese, AC | 1 |
| Sarin, LM | 1 |
| Magalhães, EJM | 1 |
| Del Sant, LC | 1 |
| B Puertas, C | 1 |
| Tuena, MA | 1 |
| Nakahira, C | 1 |
| Fava, VA | 1 |
| Delfino, R | 1 |
| Surjan, J | 1 |
| Steiglich, MS | 1 |
| Barbosa, M | 1 |
| Abdo, G | 1 |
| Cohrs, FM | 1 |
| Liberatori, A | 1 |
| Del Porto, JA | 1 |
| Lacerda, AL | 1 |
| B Andreoli, S | 1 |
| Weinbroum, AA | 1 |
| Reddy, BR | 1 |
| Babu, NS | 1 |
| Das, T | 1 |
| Bhattacharya, D | 1 |
| Murthy, CLN | 1 |
| Kumar, A | 2 |
| Idris, MM | 1 |
| Chakravarty, S | 1 |
| Zarate, CA | 2 |
| Daly, EJ | 1 |
| Turkoz, I | 1 |
| Salvadore, G | 1 |
| Fedgchin, M | 1 |
| Ionescu, DF | 3 |
| Starr, HL | 1 |
| Borentain, S | 1 |
| Trivedi, MH | 2 |
| Thase, ME | 1 |
| Singh, JB | 1 |
| Rosa, JM | 1 |
| Zeni, ALB | 1 |
| Kaster, MP | 1 |
| Ceban, F | 1 |
| Lui, LMW | 1 |
| Lee, JG | 1 |
| Chau, EH | 1 |
| Cao, B | 1 |
| Ho, RC | 1 |
| Medlicott, NJ | 1 |
| Harland, S | 1 |
| Anderson-Fahey, B | 1 |
| Le Nedelec, M | 1 |
| McNaughton, N | 2 |
| Canpolat, DG | 1 |
| Yildirim, MD | 1 |
| Kutuk, N | 1 |
| Dogruel, F | 1 |
| Ocak, H | 1 |
| Aksu, R | 1 |
| Alkan, A | 1 |
| Onaolapo, OJ | 1 |
| Paul, TB | 1 |
| Onaolapo, AY | 1 |
| Castle, C | 1 |
| Pearce, JI | 1 |
| Brousseau, DC | 1 |
| Yan, K | 1 |
| Hainsworth, KR | 1 |
| Hoffmann, RG | 1 |
| Drendel, AL | 1 |
| Qiao, H | 1 |
| Jia, J | 1 |
| Guarraci, FA | 1 |
| Gonzalez, CMF | 1 |
| Lucero, D | 1 |
| Womble, PD | 1 |
| Abdel-Rahim, H | 1 |
| DeVore, J | 1 |
| Kunkel, MN | 1 |
| Quadlander, E | 1 |
| Stinnett, M | 1 |
| Boyette-Davis, J | 1 |
| Fantacci, C | 1 |
| Fabrizio, GC | 1 |
| Ferrara, P | 1 |
| Franceschi, F | 1 |
| Chiaretti, A | 2 |
| Olescowicz, G | 1 |
| Moretti, M | 1 |
| Siteneski, A | 1 |
| Tavares, MK | 1 |
| Azevedo, D | 1 |
| Colla, ARS | 1 |
| Fallon, MT | 2 |
| Wilcock, A | 1 |
| Kelly, CA | 1 |
| Paul, J | 1 |
| Lewsley, LA | 1 |
| Norrie, J | 1 |
| Laird, BJA | 1 |
| Shadli, SM | 1 |
| Kawe, T | 1 |
| Martin, D | 1 |
| Tuncalı, B | 1 |
| Araz, C | 1 |
| Çelebi, A | 1 |
| Aguilar-Valles, A | 1 |
| Haji, N | 1 |
| De Gregorio, D | 1 |
| Matta-Camacho, E | 1 |
| Eslamizade, MJ | 1 |
| Popic, J | 1 |
| Sharma, V | 1 |
| Cao, R | 1 |
| Rummel, C | 1 |
| Tanti, A | 1 |
| Wiebe, S | 1 |
| Nuñez, N | 1 |
| Comai, S | 1 |
| Nadon, R | 1 |
| Luheshi, G | 1 |
| Mechawar, N | 1 |
| Turecki, G | 2 |
| Lacaille, JC | 1 |
| Gobbi, G | 1 |
| Sonenberg, N | 1 |
| Chen, YW | 1 |
| Sherpa, AD | 1 |
| Aoki, C | 1 |
| Salloum, NC | 1 |
| Fava, M | 1 |
| Freeman, MP | 1 |
| Flynn, M | 1 |
| Hoeppner, B | 1 |
| Hock, RS | 1 |
| Cusin, C | 1 |
| Iosifescu, DV | 1 |
| Sanacora, G | 1 |
| Mathew, SJ | 1 |
| Debattista, C | 1 |
| Papakostas, GI | 1 |
| Akhlaghi, N | 1 |
| Payandemehr, P | 1 |
| Yaseri, M | 1 |
| Akhlaghi, AA | 1 |
| Abdolrazaghnejad, A | 1 |
| Pitsikas, N | 2 |
| Georgiadou, G | 1 |
| Delis, F | 1 |
| Antoniou, K | 1 |
| Liu, L | 1 |
| Yang, X | 1 |
| Gao, H | 1 |
| Tang, QK | 1 |
| Yin, LY | 1 |
| Yin, XY | 1 |
| Hao, JR | 1 |
| Geng, DQ | 1 |
| Gao, C | 1 |
| Aust, S | 1 |
| Gärtner, M | 1 |
| Basso, L | 1 |
| Otte, C | 1 |
| Wingenfeld, K | 1 |
| Chae, WR | 1 |
| Heuser-Collier, I | 1 |
| Regen, F | 1 |
| Cosma, NC | 1 |
| van Hall, F | 1 |
| Grimm, S | 1 |
| Bajbouj, M | 1 |
| Wąsik, A | 1 |
| Białoń, M | 1 |
| Żarnowska, M | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Schatzberg, AF | 2 |
| Verdonk, F | 1 |
| Petit, AC | 1 |
| Abdel-Ahad, P | 1 |
| Vinckier, F | 1 |
| Jouvion, G | 1 |
| de Maricourt, P | 1 |
| De Medeiros, GF | 1 |
| Danckaert, A | 1 |
| Van Steenwinckel, J | 1 |
| Blatzer, M | 1 |
| Maignan, A | 1 |
| Langeron, O | 1 |
| Sharshar, T | 1 |
| Callebert, J | 1 |
| Launay, JM | 1 |
| Chrétien, F | 1 |
| Gaillard, R | 1 |
| Ren, W | 1 |
| Liu, X | 2 |
| Cheng, L | 1 |
| Wang, G | 1 |
| Peng, L | 1 |
| Li, Q | 1 |
| Wu, HR | 1 |
| Fan, SJ | 1 |
| Liu, DX | 1 |
| Jiang, H | 1 |
| Zhang, Q | 1 |
| Pan, F | 1 |
| Chaki, S | 1 |
| Niciu, MJ | 2 |
| Grunschel, BD | 1 |
| Corlett, PR | 1 |
| Pittenger, C | 1 |
| Bloch, MH | 1 |
| Parise, EM | 1 |
| Alcantara, LF | 1 |
| Warren, BL | 1 |
| Wright, KN | 1 |
| Hadad, R | 1 |
| Sial, OK | 1 |
| Kroeck, KG | 1 |
| Iñiguez, SD | 1 |
| Bolaños-Guzmán, CA | 1 |
| Liang, HJ | 1 |
| Tang, A | 1 |
| Chan, F | 1 |
| Sufka, KJ | 1 |
| White, SW | 1 |
| Blednov, YA | 1 |
| Benavidez, JM | 1 |
| Black, M | 1 |
| Leiter, CR | 1 |
| Osterndorff-Kahanek, E | 1 |
| Johnson, D | 1 |
| Borghese, CM | 1 |
| Hanrahan, JR | 1 |
| Johnston, GA | 1 |
| Chebib, M | 1 |
| Harris, RA | 1 |
| Kilic, FS | 1 |
| Ismailoglu, S | 1 |
| Kaygisiz, B | 1 |
| Oner, S | 1 |
| Luckenbaugh, DA | 1 |
| Richards, EM | 1 |
| Raud, S | 1 |
| Reimets, R | 1 |
| Loomets, M | 1 |
| Sütt, S | 1 |
| Altpere, A | 1 |
| Visnapuu, T | 1 |
| Innos, J | 1 |
| Luuk, H | 1 |
| Plaas, M | 1 |
| Volke, V | 1 |
| Vasar, E | 1 |
| Moitra, VK | 1 |
| Patel, MK | 1 |
| Darrah, D | 1 |
| Moitra, A | 1 |
| Wunsch, H | 1 |
| Brachman, RA | 1 |
| McGowan, JC | 1 |
| Perusini, JN | 1 |
| Lim, SC | 1 |
| Pham, TH | 1 |
| Faye, C | 1 |
| Gardier, AM | 1 |
| Mendez-David, I | 1 |
| David, DJ | 1 |
| Hen, R | 1 |
| Denny, CA | 1 |
| Melo, A | 1 |
| Kokras, N | 1 |
| Dalla, C | 1 |
| Ferreira, C | 1 |
| Ventura-Silva, AP | 1 |
| Sousa, N | 1 |
| Pêgo, JM | 1 |
| De Campos, EG | 1 |
| Bruni, AT | 1 |
| De Martinis, BS | 1 |
| Sobota, R | 1 |
| Mihara, T | 1 |
| Forrest, A | 1 |
| Featherstone, RE | 1 |
| Siegel, SJ | 1 |
| Willner, P | 1 |
| Belzung, C | 1 |
| Pittman, J | 1 |
| Hylton, A | 1 |
| Bolton, JM | 1 |
| Gunnell, D | 1 |
| Reardon, S | 1 |
| Trevlopoulou, A | 1 |
| Touzlatzi, N | 1 |
| Fan, N | 1 |
| Rosenheck, R | 1 |
| Wang, D | 1 |
| Ke, X | 1 |
| Ding, Y | 1 |
| Sun, B | 1 |
| Zhou, C | 1 |
| Deng, X | 1 |
| Tang, W | 1 |
| He, H | 1 |
| Holubova, K | 1 |
| Kleteckova, L | 1 |
| Skurlova, M | 1 |
| Ricny, J | 1 |
| Stuchlik, A | 1 |
| Vales, K | 1 |
| Thelen, C | 1 |
| Sens, J | 1 |
| Mauch, J | 1 |
| Pandit, R | 1 |
| Pitychoutis, PM | 1 |
| Sun, XR | 1 |
| Zhang, ZZ | 1 |
| Zhao, HT | 1 |
| Li, HH | 1 |
| Ji, MH | 1 |
| Li, KY | 1 |
| Yang, JJ | 1 |
| Félix, LM | 1 |
| Antunes, LM | 1 |
| Coimbra, AM | 1 |
| Valentim, AM | 1 |
| Engin, E | 1 |
| Treit, D | 1 |
| Dickson, CT | 1 |
| Ruggiero, A | 1 |
| Barone, G | 1 |
| Antonelli, A | 1 |
| Lazzareschi, I | 1 |
| Genovese, O | 1 |
| Paiano, S | 1 |
| Sammartino, M | 1 |
| Maurizi, P | 1 |
| Riccardi, R | 1 |
| Jain, K | 1 |
| Ghai, B | 1 |
| Saxena, AK | 1 |
| Saini, D | 1 |
| Khandelwal, N | 1 |
| Irwin, SA | 1 |
| Iglewicz, A | 1 |
| Khademi, S | 1 |
| Ghaffarpasand, F | 1 |
| Heiran, HR | 1 |
| Yavari, MJ | 1 |
| Motazedian, S | 1 |
| Dehghankhalili, M | 1 |
| Darlong, V | 1 |
| Shende, D | 1 |
| Singh, M | 1 |
| Garg, R | 1 |
| Pandey, R | 1 |
| Punj, J | 1 |
| Hosseini Jahromi, SA | 1 |
| Hosseini Valami, SM | 1 |
| Adeli, N | 1 |
| Yazdi, Z | 1 |
| Loss, CM | 1 |
| Córdova, SD | 1 |
| de Oliveira, DL | 1 |
| Alletag, MJ | 1 |
| Auerbach, MA | 1 |
| Baum, CR | 1 |
| Krupitsky, E | 1 |
| Burakov, A | 1 |
| Romanova, T | 1 |
| Dunaevsky, I | 1 |
| Strassman, R | 1 |
| Grinenko, A | 1 |
| Silvestre, JS | 1 |
| Pallarés, M | 1 |
| Nadal, R | 1 |
| Ferré, N | 1 |
| Shi, L | 1 |
| Fatemi, SH | 1 |
| Sidwell, RW | 1 |
| Patterson, PH | 1 |
| Becker, A | 1 |
| Peters, B | 1 |
| Schroeder, H | 1 |
| Mann, T | 1 |
| Huether, G | 1 |
| Grecksch, G | 1 |
| Hayase, T | 1 |
| Yamamoto, Y | 1 |
| Yamamoto, K | 1 |
| Pavarin, RM | 1 |
| Ryhänen, P | 1 |
| Kangas, T | 1 |
| Rantakylä, S | 1 |
| Warner, DL | 1 |
| Cabaret, J | 1 |
| Velling, D | 1 |
| Lipp, M | 1 |
| Daubländer, M | 1 |
| Sebastian, M | 1 |
| Dick, W | 2 |
| Kennedy, RM | 2 |
| Porter, FL | 1 |
| Miller, JP | 1 |
| Jaffe, DM | 1 |
| Carpenter, WT | 1 |
| Sherwin, TS | 1 |
| Green, SM | 2 |
| Khan, A | 1 |
| Chapman, DS | 1 |
| Dannenberg, B | 1 |
| McAllister, JD | 1 |
| Weiner, AL | 1 |
| Vieira, L | 1 |
| McKay, CA | 1 |
| Bayer, MJ | 1 |
| Oda, A | 1 |
| Iida, H | 1 |
| Dohi, S | 1 |
| Younge, PA | 1 |
| Kendall, JM | 1 |
| Krauss, B | 1 |
| Babar, E | 1 |
| Ozgünen, T | 1 |
| Melik, E | 1 |
| Polat, S | 1 |
| Akman, H | 1 |
| Krupitsky, EM | 1 |
| Burakov, AM | 1 |
| Romanova, TN | 1 |
| Grinenko, NI | 1 |
| Grinenko, AY | 1 |
| Fletcher, J | 1 |
| Petrakis, IL | 1 |
| Krystal, JH | 1 |
| Mitchell, AC | 1 |
| Knoche, E | 1 |
| Traub, E | 1 |
| Sappington, AA | 2 |
| Corssen, G | 2 |
| Becker, AT | 2 |
| Tavakoli, M | 2 |
| Modvig, KM | 1 |
| Nielsen, SF | 1 |
| Korttila, K | 1 |
| Levänen, J | 1 |
| Kaplan, S | 1 |
| Hirschowitz, AS | 1 |
| Nakamura, R | 1 |
| Johnson, NE | 1 |
| Mendoza Mendoza, A | 1 |
| Solano Reina, E | 1 |
| Mogensen, JV | 1 |
| Misfeldt, BB | 1 |
| Hanel, HK | 1 |
| Magbagbeola, JA | 1 |
| Thomas, NA | 1 |
| Garfield, JM | 1 |
| Garfield, FB | 1 |
| Stone, JG | 1 |
| Hopkins, D | 1 |
| Johns, LA | 1 |
| Unni, VK | 1 |
| Bovill, JG | 1 |
| Crusius, HG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression[NCT02418585] | Phase 3 | 236 participants (Actual) | Interventional | 2015-08-07 | Completed | ||
| Ketamine Infusion for Social Anxiety Disorder[NCT02083926] | Early Phase 1 | 18 participants (Actual) | Interventional | 2015-01-02 | Completed | ||
| Pediatric Procedural Sedation and the Relationship With Post-Discharge Negative Behavioral Changes in the Emergency Department[NCT03980067] | 201 participants (Actual) | Interventional | 2019-05-17 | Completed | |||
| Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Emergency Department: a Double Blind Randomized Versus Placebo Controlled Trial[NCT06181695] | Phase 3 | 182 participants (Anticipated) | Interventional | 2024-05-02 | Not yet recruiting | ||
| Intranasal Dexmedetomidine and Fentanyl Versus Intravenous Midazolam and Ketamine in Sedation for Painful Outpatient Procedures[NCT04621110] | Phase 3 | 60 participants (Anticipated) | Interventional | 2021-06-01 | Not yet recruiting | ||
| A Pilot Study of the Use of Oral Ketamine for Treatment of Vaso-Occlusive Pain in Adolescents and Young Adults[NCT05378555] | Phase 3 | 10 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| A Comparison of Midazolam or Haloperidol Premedication Versus Placebo for Reducing Ketamine Induced Agitation After Adult Procedural Sedation in the Emergency Department[NCT02909465] | Phase 4 | 185 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Positive Imagery Therapy and the Incidence of Emergence Reactions With the Use of Ketamine[NCT04746079] | 180 participants (Anticipated) | Interventional | 2021-02-05 | Recruiting | |||
| Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State[NCT06133309] | 15 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation[NCT05866575] | 136 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | |||
| Ketamine Infusion for Obsessive-Compulsive Disorder[NCT01349231] | Phase 2 | 10 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
| The Effect of Therapeutic Ketamine Infusions on the Symptoms of Post-Traumatic Stress Disorder in Combat Veterans[NCT03088384] | 30 participants (Actual) | Observational | 2016-11-28 | Completed | |||
| Ketofol Versus Fentofol for Procedural Sedation of Children 3 to 17 Years Old: a Double-Blind Randomized Controlled Trial[NCT02079090] | Phase 3 | 30 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| Anxiolysis for Emergency Department Procedures in Pediatric Patients Using Intranasal Ketamine Compared With Intranasal Midazolam: A Randomized Controlled Trial[NCT03043430] | Phase 4 | 10 participants (Actual) | Interventional | 2016-05-31 | Terminated (stopped due to Research manpower shortage) | ||
| Ketamine Versus Etomidate for Procedural Sedation for Pediatric Orthopedic Reductions[NCT00596050] | Phase 4 | 50 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Systemic Absorption of Lidocaine After Ultrasound Guided Hematoma Block for Reduction of Different Types of Pediatric Distal Radius Fractures[NCT04359017] | Phase 4 | 0 participants (Actual) | Interventional | 2020-11-01 | Withdrawn (stopped due to Sponsoring staff have left institution) | ||
| Midazolam Effect on Agitation Postnasal Surgery: A Double Blinded Randomized Controlled Trial[NCT05165914] | 100 participants (Actual) | Interventional | 2021-05-27 | Completed | |||
| Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607] | Phase 3 | 2 participants (Actual) | Interventional | 2020-01-14 | Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Median) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -2.0 |
| Intranasal Placebo Plus Oral AD | -2.0 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). (NCT02418585)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 29.1 |
| Intranasal Placebo Plus Oral AD | 20.9 |
"EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). Health Status Index range is -0.148 - 0.949, is anchored at 0 (dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) *5. Higher score indicates worst health state." (NCT02418585)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -23.2 |
| Intranasal Placebo Plus Oral AD | -17.1 |
"European Quality of Life Group-5 Dimension-5-Level (EQ-5D-5L) is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health today. Responses were used to generate a Health Status Index (HSI). Health Status Index range is -0.148 - 0.949, is anchored at 0 (dead) and 1 (full health)." (NCT02418585)
Timeframe: Baseline up to End of Double-blind Induction Phase (Day 28)
| Intervention | Units on a Scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 0.288 |
| Intranasal Placebo Plus Oral AD | 0.231 |
"GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -7.9 |
| Intranasal Placebo Plus Oral AD | -6.8 |
MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. (NCT02418585)
Timeframe: Baseline up to Day 28 of Double-blind Induction Phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -21.4 |
| Intranasal Placebo Plus Oral AD | -17.0 |
"MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -19.6 |
| Intranasal Placebo Plus Oral AD | -16.3 |
PHQ-9 is 9-item, self-report scale assessing depressive symptoms. Each item is rated on 4-point scale (0=Not at all, 1=Several Days, 2=More than half days, 3=Nearly every day. Scale scores each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria and it has been used both as screening tool and measure of response to treatment for depression. The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). (NCT02418585)
Timeframe: Baseline up to Day 28 of Double-blind Induction phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -13.0 |
| Intranasal Placebo Plus Oral AD | -10.2 |
"PHQ-9 is 9-item, self-report scale assessing depressive symptoms. Each item is rated on 4-point scale (0=Not at all, 1=Several Days, 2=More than half days, 3=Nearly every day). Scale scores each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria and it has been used both as screening tool and measure of response to treatment for depression. The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -12.2 |
| Intranasal Placebo Plus Oral AD | -10.1 |
The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. (NCT02418585)
Timeframe: Baseline up to Day 28 of Double-blind Induction phase
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -13.6 |
| Intranasal Placebo Plus Oral AD | -9.4 |
"The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Units on a scale (Mean) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | -12.5 |
| Intranasal Placebo Plus Oral AD | -9.3 |
"Remission was defined as participants who had a MADRS total score of less than or equal to (=<) 12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: At Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 48.2 |
| Intranasal Placebo Plus Oral AD | 30.3 |
Remission defined as SDS total score <= 6 and individual item scores each <= 2. SDS is a participant reported outcome measure and is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items were summed to create a total score of 0-30 where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when under productive. (NCT02418585)
Timeframe: At Day 28 (End of Double-blind Induction Phase)
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 39.5 |
| Intranasal Placebo Plus Oral AD | 20.9 |
Response defined as SDS total score <= 12 and individual item scores each <= 4. SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. (NCT02418585)
Timeframe: At Day 28 [end of Double-blind Induction Phase]
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 57.0 |
| Intranasal Placebo Plus Oral AD | 39.5 |
"MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The percentage of participants with greater than or equal to (>=) 50 % reduction from baseline in MADRS total score was reported. The last post baseline observation during the phase was carried forward as End Point for that phase." (NCT02418585)
Timeframe: At Endpoint (Double-blind Induction Phase [Day 28])
| Intervention | Percentage of participants (Number) |
|---|---|
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 63.4 |
| Intranasal Placebo Plus Oral AD | 49.5 |
A participant was defined as having a clinical response if there is at least 50 percent (%) improvement from baseline in the MADRS total score with onset by Day 2 and Day 8 that was maintained to Day 28. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Participants who did not meet such criterion or discontinue during the study before Day 28 for any reason were considered as non-responders. (NCT02418585)
Timeframe: Day 2 up to Day 28 and Day 8 up to Day 28
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Onset of Clinical response on Day 2 | Onset of Clinical response on Day 8 | |
| Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) | 7.9 | 10.5 |
| Intranasal Placebo Plus Oral AD | 4.6 | 6.4 |
Clinician-administered scale for the assessment of fear and avoidance found in social phobia (SAD); it has 24 items divided into 2 subscales, 13 for performance anxiety, and 11 for social situations each rated from 0 to 3 (0=none,1=mild,2=moderate,3=definite). The sum scores for Fear and Avoidance results in an overall score (max 144 points). There are 4 clinician subscales: fear of social interaction, fear of performance, avoidance of social interaction and avoidance of performance 0 to 30= SAD is unlikely 30 to 60=SAD is probable 60 to 90=SADis very probable >90= SAD highly probable (NCT02083926)
Timeframe: Day 1 (1+28)
| Intervention | score on a scale (Mean) |
|---|---|
| Ketamine Infusion on Day 0 or Day 28 | 66.1 |
| Saline Infusion on Day 0 or Day 28 | 86.1 |
"Instrument that tries to measure anxiety, that is believed to range across a continuum of values and cannot easily be directly measured.We used a straight horizontal line of 100 mm in length. The ends were defined as the extreme limits of the parameter to be measured (anxiety); oriented from the left (no anxiety) to the right (worst anxiety ever felt). The patient marks on the line the point that they feel represents their perception of their current state.The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks.~We examined Visual Analog Scale (VAS) for anxiety symptoms at screening, 1 hour prior to infusion, 1, 2 and 3 hours after infusion, 1, 2, 3, 5, 7, 10, and 14 days following a single ketamine/saline infusion." (NCT02083926)
Timeframe: Day 1 (1+28)
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine Infusion on Day 0 or Day 28 | 12.1 |
| Saline Infusion on Day 0 or Day 28 | 19.6 |
We will examine change from baseline in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) ratings of OCD severity at 1 day following infusion. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) assesses obsessive and compulsive symptom severity. Obsessions are rated on a scale from 0-20 and compulsions are rated on a scale of 0-20, for a total scale of 0-40. Scores on the obsessions scale and scores on the compulsions scale are summed to obtain the total score. The higher the score, the more severe the OCD. (NCT01349231)
Timeframe: Baseline and 1 day after ketamine infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | -2.7 |
We will examine change from baseline in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) ratings of OCD severity at 2 days following infusion. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) assesses obsessive and compulsive symptom severity. Obsessions are rated on a scale from 0-20 and compulsions are rated on a scale of 0-20, for a total scale of 0-40. Scores on the obsessions scale and scores on the compulsions scale are summed to obtain the total score. The higher the score, the more severe the OCD. (NCT01349231)
Timeframe: Baseline and 2 days following infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | -3.6 |
We will examine change from baseline in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) ratings of OCD severity at 3 days following infusion. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) assesses obsessive and compulsive symptom severity. Obsessions are rated on a scale from 0-20 and compulsions are rated on a scale of 0-20, for a total scale of 0-40. Scores on the obsessions scale and scores on the compulsions scale are summed to obtain the total score. The higher the score, the more severe the OCD. (NCT01349231)
Timeframe: Baseline and 3 days following infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | -2.9 |
We will examine change from baseline in Hamilton Rating Scale for Depression (HRDS) ratings of depression severity at day 1-3 following a single ketamine infusion. The HRDS assesses severity of, and change in, depressive symptoms. The HRDS is a 21 item scale with scores ranging from 0-66. The higher the score, the more severe the depression. (NCT01349231)
Timeframe: Baseline, Day 1, Day 2, and Day 3
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| HRDS change from Baseline to Day 1 | HRDS change from Baseline to Day 2 | HRDS change from Baseline to Day 3 | |
| Ketamine | -6.57 | -7.29 | -5.14 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 1.17 |
| Placebo - Healthy Volunteers | 1.48 |
| Ketamine - MDD Patients | 33.83 |
| Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 2.45 |
| Placebo - Healthy Volunteers | 0.67 |
| Ketamine - MDD Patients | 23.73 |
| Placebo - MDD Patients | 30.68 |
17 reviews available for ketamine and Anxiety
| Article | Year |
|---|---|
Ketamine treatment for refractory anxiety: A systematic review.
Topics: Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate | 2022 |
Neurobiological, behavioral, and cognitive effects of ketamine in adolescents: A review of human and pre-clinical research.
Topics: Adolescent; Adult; Animals; Anxiety; Behavior, Animal; Cognition; Depression; Female; Humans; Ketami | 2022 |
The role of mGlu
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Ketamine; Receptors, Metabotropic Glutamate | 2022 |
Comment on 'Ketamine treatment for refractory anxiety: A systematic review'.
Topics: Anxiety; Humans; Ketamine | 2023 |
Treatment-Resistant Late-Life Depression: A Review of Clinical Features, Neuropsychology, Neurobiology, and Treatment.
Topics: Aged; Alzheimer Disease; Anxiety; Depressive Disorder, Treatment-Resistant; Diagnosis, Differential; | 2023 |
Ketamine effects on anxiety and fear-related behaviors: Current literature evidence and new findings.
Topics: Animals; Anxiety; Avoidance Learning; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Fear; | 2020 |
Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions.
Topics: Antidepressive Agents; Anxiety; Depression; Ketamine; Neural Pathways; Prefrontal Cortex | 2020 |
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et
Topics: Adult; Antidepressive Agents; Anxiety; Canada; Depressive Disorder, Major; Humans; Ketamine | 2021 |
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders.
Topics: Administration, Intranasal; Administration, Intravenous; Antidepressive Agents; Anxiety; Disease Man | 2021 |
Intranasal drug administration for procedural sedation in children admitted to pediatric Emergency Room.
Topics: Administration, Intranasal; Anxiety; Emergency Service, Hospital; Humans; Hypnotics and Sedatives; K | 2018 |
Intranasal drug administration for procedural sedation in children admitted to pediatric Emergency Room.
Topics: Administration, Intranasal; Anxiety; Emergency Service, Hospital; Humans; Hypnotics and Sedatives; K | 2018 |
Intranasal drug administration for procedural sedation in children admitted to pediatric Emergency Room.
Topics: Administration, Intranasal; Anxiety; Emergency Service, Hospital; Humans; Hypnotics and Sedatives; K | 2018 |
Intranasal drug administration for procedural sedation in children admitted to pediatric Emergency Room.
Topics: Administration, Intranasal; Anxiety; Emergency Service, Hospital; Humans; Hypnotics and Sedatives; K | 2018 |
Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major Depression.
Topics: Antidepressive Agents; Anxiety; Biomedical Research; Depressive Disorder, Major; Diagnostic and Stat | 2019 |
mGlu2/3 receptor antagonists.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Humans; Ketamine; Receptors, Metabotropic Gluta | 2019 |
Treatment-resistant depression: are animal models of depression fit for purpose?
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Depressive Disorder, Treatment-Resistant; Disea | 2015 |
Development of New Psychopharmacological Agents for Depression and Anxiety.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Botulinum Toxins; Depression; Excitatory Amino | 2015 |
Suicide risk assessment and intervention in people with mental illness.
Topics: Antidepressive Agents; Antipsychotic Agents; Anxiety; Cognitive Behavioral Therapy; Crisis Intervent | 2015 |
Ketamine, propofol, and ketofol use for pediatric sedation.
Topics: Adolescent; Amnesia; Analgesia; Analgesics, Non-Narcotic; Anesthetics, Dissociative; Antiemetics; An | 2012 |
Management of acute pain and anxiety in children undergoing procedures in the emergency department.
Topics: Acute Disease; Analgesia; Analgesics; Anesthesia, Local; Anxiety; Child; Child, Hospitalized; Emerge | 2001 |
29 trials available for ketamine and Anxiety
| Article | Year |
|---|---|
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial.
Topics: Anxiety; COVID-19; Depression; Humans; Ketamine; Pandemics; Prospective Studies; Telemedicine | 2022 |
Analgo-Sedative Effects of Oral or Nebulized Ketamine in Preschoolers Undergoing Elective Surgery: A Comparative, Randomized, Double-Blind Study.
Topics: Administration, Oral; Analgesics; Anesthesia Recovery Period; Anxiety; Child; Child, Preschool; Doub | 2020 |
Using classification and regression tree modelling to investigate treatment response to a single low-dose ketamine infusion: Post hoc pooled analyses of randomized placebo-controlled and open-label trials.
Topics: Antidepressive Agents; Anxiety; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intrave | 2021 |
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.
Topics: Adult; Anxiety; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Ther | 2021 |
Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Depression; Depressiv | 2017 |
Comparison of ketamine-propofol and ketamine-dexmedetomidine combinations in children for sedation during tooth extraction.
Topics: Anesthetics, Dissociative; Anxiety; Child; Child, Preschool; Deep Sedation; Dexmedetomidine; Female; | 2017 |
Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders.
Topics: Adolescent; Anxiety; Anxiety Disorders; Dissociative Disorders; Double-Blind Method; Humans; Ketamin | 2017 |
Pediatric premedication: a double-blind randomized trial of dexmedetomidine or ketamine alone versus a combination of dexmedetomidine and ketamine.
Topics: Age Factors; Analgesics; Anxiety; Child, Preschool; Dexmedetomidine; Double-Blind Method; Drug Thera | 2017 |
Oral Ketamine vs Placebo in Patients With Cancer-Related Neuropathic Pain: A Randomized Clinical Trial.
Topics: Aged; Analgesics; Antineoplastic Agents; Anxiety; Cancer Pain; Cognition Disorders; Depression; Doub | 2018 |
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.
Topics: Adult; Anxiety; Anxiety Disorders; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2019 |
Premedication With Midazolam or Haloperidol to Prevent Recovery Agitation in Adults Undergoing Procedural Sedation With Ketamine: A Randomized Double-Blind Clinical Trial.
Topics: Administration, Intravenous; Adult; Anxiety; Conscious Sedation; Double-Blind Method; Emergency Serv | 2019 |
Premedication With Midazolam or Haloperidol to Prevent Recovery Agitation in Adults Undergoing Procedural Sedation With Ketamine: A Randomized Double-Blind Clinical Trial.
Topics: Administration, Intravenous; Adult; Anxiety; Conscious Sedation; Double-Blind Method; Emergency Serv | 2019 |
Premedication With Midazolam or Haloperidol to Prevent Recovery Agitation in Adults Undergoing Procedural Sedation With Ketamine: A Randomized Double-Blind Clinical Trial.
Topics: Administration, Intravenous; Adult; Anxiety; Conscious Sedation; Double-Blind Method; Emergency Serv | 2019 |
Premedication With Midazolam or Haloperidol to Prevent Recovery Agitation in Adults Undergoing Procedural Sedation With Ketamine: A Randomized Double-Blind Clinical Trial.
Topics: Administration, Intravenous; Adult; Anxiety; Conscious Sedation; Double-Blind Method; Emergency Serv | 2019 |
Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
Topics: Antidepressive Agents; Anxiety; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant | 2019 |
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression.
Topics: Adult; Affect; Anxiety; Anxiety Disorders; Bipolar Disorder; Cross-Over Studies; Depression; Double- | 2015 |
Efficacy of two oral premedicants: midazolam or a low-dose combination of midazolam-ketamine for reducing stress during intravenous cannulation in children undergoing CT imaging.
Topics: Administration, Oral; Anesthetics, Dissociative; Anti-Anxiety Agents; Anxiety; Catheterization, Peri | 2010 |
Intravenous and peritonsillar infiltration of ketamine for postoperative pain after adenotonsillectomy: a randomized placebo-controlled clinical trial.
Topics: Adenoidectomy; Adolescent; Analysis of Variance; Anesthetics, Dissociative; Antiemetics; Anxiety; Ch | 2011 |
Low- versus high-dose combination of midazolam-ketamine for oral premedication in children for ophthalmologic surgeries.
Topics: Anti-Anxiety Agents; Anxiety; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blin | 2011 |
Comparison of the effects of intranasal midazolam versus different doses of intranasal ketamine on reducing preoperative pediatric anxiety: a prospective randomized clinical trial.
Topics: Administration, Intranasal; Anesthesia; Anxiety; Blood Pressure; Child; Child, Preschool; Conscious | 2012 |
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up.
Topics: Adolescent; Adult; Anesthetics, Dissociative; Anxiety; Attitude; Depression; Double-Blind Method; Fe | 2002 |
Ketamine plus midazolam, a most effective paediatric oral premedicant.
Topics: Adjuvants, Anesthesia; Administration, Oral; Anesthesia, Inhalation; Anesthetics, Dissociative; Anxi | 1995 |
[Analgesia-sedation for maxillo-facial surgery with midazolam-pentazocine and miazolam-ketamine. Clinical double-blind study of anxiety, analgesia, sedation and amnesia].
Topics: Adjuvants, Anesthesia; Adult; Ambulatory Surgical Procedures; Amnesia; Analgesia; Anesthesia; Anesth | 1995 |
Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies.
Topics: Adolescent; Analgesics, Opioid; Anesthetics, Dissociative; Anti-Anxiety Agents; Anxiety; Child; Chil | 1998 |
Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies.
Topics: Adolescent; Analgesics, Opioid; Anesthetics, Dissociative; Anti-Anxiety Agents; Anxiety; Child; Chil | 1998 |
Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies.
Topics: Adolescent; Analgesics, Opioid; Anesthetics, Dissociative; Anti-Anxiety Agents; Anxiety; Child; Chil | 1998 |
Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies.
Topics: Adolescent; Analgesics, Opioid; Anesthetics, Dissociative; Anti-Anxiety Agents; Anxiety; Child; Chil | 1998 |
Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies.
Topics: Adolescent; Analgesics, Opioid; Anesthetics, Dissociative; Anti-Anxiety Agents; Anxiety; Child; Chil | 1998 |
Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies.
Topics: Adolescent; Analgesics, Opioid; Anesthetics, Dissociative; Anti-Anxiety Agents; Anxiety; Child; Chil | 1998 |
Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies.
Topics: Adolescent; Analgesics, Opioid; Anesthetics, Dissociative; Anti-Anxiety Agents; Anxiety; Child; Chil | 1998 |
Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies.
Topics: Adolescent; Analgesics, Opioid; Anesthetics, Dissociative; Anti-Anxiety Agents; Anxiety; Child; Chil | 1998 |
Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies.
Topics: Adolescent; Analgesics, Opioid; Anesthetics, Dissociative; Anti-Anxiety Agents; Anxiety; Child; Chil | 1998 |
The schizophrenia ketamine challenge study debate.
Topics: Anesthetics, Dissociative; Anxiety; Bioethics; Brief Psychiatric Rating Scale; Consumer Product Safe | 1999 |
Does adjunctive midazolam reduce recovery agitation after ketamine sedation for pediatric procedures? A randomized, double-blind, placebo-controlled trial.
Topics: Adjuvants, Anesthesia; Adolescent; Anesthesia Recovery Period; Anesthetics, Dissociative; Anti-Anxie | 2000 |
Does adjunctive midazolam reduce recovery agitation after ketamine sedation for pediatric procedures? A randomized, double-blind, placebo-controlled trial.
Topics: Adjuvants, Anesthesia; Adolescent; Anesthesia Recovery Period; Anesthetics, Dissociative; Anti-Anxie | 2000 |
Does adjunctive midazolam reduce recovery agitation after ketamine sedation for pediatric procedures? A randomized, double-blind, placebo-controlled trial.
Topics: Adjuvants, Anesthesia; Adolescent; Anesthesia Recovery Period; Anesthetics, Dissociative; Anti-Anxie | 2000 |
Does adjunctive midazolam reduce recovery agitation after ketamine sedation for pediatric procedures? A randomized, double-blind, placebo-controlled trial.
Topics: Adjuvants, Anesthesia; Adolescent; Anesthesia Recovery Period; Anesthetics, Dissociative; Anti-Anxie | 2000 |
Patient anxiety scores after low-dose ketamine or fentanyl for epidural catheter placement.
Topics: Adult; Analgesia, Epidural; Anesthetics, Dissociative; Anesthetics, Intravenous; Anxiety; Female; Fe | 2000 |
Sedation for children requiring wound repair: a randomised controlled double blind comparison of oral midazolam and oral ketamine.
Topics: Administration, Oral; Anxiety; Child; Child, Preschool; Conscious Sedation; Dose-Response Relationsh | 2001 |
Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists.
Topics: Adult; Affect; Alcoholism; Anxiety; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Ty | 2001 |
A single infusion of intravenous ketamine improves pain relief in patients with critical limb ischaemia: results of a double blind randomised controlled trial.
Topics: Aged; Analgesics; Analgesics, Opioid; Anxiety; Depression; Double-Blind Method; Extremities; Female; | 2002 |
[Effects of diazepam and flunitrazepam on the undesired postoperative side-effects of ketamine anaesthesia (author's transl)].
Topics: Adult; Anti-Anxiety Agents; Anxiety; Atropine; Diazepam; Double-Blind Method; Female; Flunitrazepam; | 1978 |
Psychological changes in children after anaesthesia: a comparison between halothane and ketamine.
Topics: Affective Symptoms; Anesthesia; Anxiety; Child; Child, Hospitalized; Child, Preschool; Halothane; Hu | 1977 |
92 other studies available for ketamine and Anxiety
| Article | Year |
|---|---|
Prophylactic efficacy of ketamine, but not the low-trapping NMDA receptor antagonist AZD6765, against stress-induced maladaptive behavior and 4E-BP1-related synaptic protein synthesis impairment.
Topics: Adaptor Proteins, Signal Transducing; Analgesics; Animals; Antidepressive Agents; Anxiety; Behavior, | 2022 |
Ketamine acutely impairs memory consolidation and repeated exposure promotes stereotyped behavior without changing anxiety- and aggression-like parameters in adult zebrafish.
Topics: Aggression; Animals; Anxiety; Behavior, Animal; Hydrocortisone; Ketamine; Memory Consolidation; Ster | 2022 |
Ketamine sex- and dose-dependently mitigates behavioral sequelae induced by a predator-based psychosocial stress model of post-traumatic stress disorder.
Topics: Animals; Anxiety; Disease Models, Animal; Female; Ketamine; Male; Rats; Rats, Sprague-Dawley; Stress | 2022 |
Antianhedonic effects of serial intravenous subanaesthetic ketamine in anxious versus nonanxious depression.
Topics: Antidepressive Agents; Anxiety; Depression; Depressive Disorder, Major; Depressive Disorder, Treatme | 2022 |
Clinical Effectiveness of Intravenous Racemic Ketamine Infusions in a Large Community Sample of Patients With Treatment-Resistant Depression, Suicidal Ideation, and Generalized Anxiety Symptoms: A Retrospective Chart Review.
Topics: Anxiety; Depression; Depressive Disorder, Major; Humans; Ketamine; Retrospective Studies; Suicidal I | 2022 |
Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study.
Topics: Adult; Anxiety; Anxiety Disorders; Cohort Studies; Depression; Depressive Disorder, Major; Humans; K | 2022 |
The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Depressive Disorder, Major; Female; | 2023 |
The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Depressive Disorder, Major; Female; | 2023 |
The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Depressive Disorder, Major; Female; | 2023 |
The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Depressive Disorder, Major; Female; | 2023 |
One binge-type cycle of alcohol plus ketamine exposure induces emotional-like disorders associated with oxidative damage in adolescent female rats.
Topics: Alcoholism; Animals; Anxiety; Ethanol; Female; Ketamine; Oxidative Stress; Prefrontal Cortex; Rats | 2023 |
Activation of ventral hippocampal CB1 receptors inhibits ketamine-induced anxiogenic-like behavior: Alteration of BDNF/c-Fos levels in the mouse hippocampus.
Topics: Animals; Anxiety; Brain-Derived Neurotrophic Factor; Hippocampus; Ketamine; Male; Mice; Mice, Inbred | 2023 |
The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis.
Topics: Anxiety; Anxiety Disorders; Depression; Humans; Ketamine; Retrospective Studies | 2023 |
A single dose of ketamine enhances early life stress-induced aggression with no effect on fear memory, anxiety-like behavior, or depression-like behavior in mice.
Topics: Adverse Childhood Experiences; Aggression; Animals; Anxiety; Depression; Fear; Humans; Ketamine; Mic | 2023 |
Ketamine metabolite alleviates morphine withdrawal-induced anxiety via modulating nucleus accumbens parvalbumin neurons in male mice.
Topics: Analgesics, Opioid; Animals; Anxiety; Anxiety Disorders; Ketamine; Male; Mice; Morphine; Neurons; Nu | 2023 |
A new approach to explore the correlation between declarative memory and anxiety in animal models of schizophrenia and microplastic pollution.
Topics: Animals; Anxiety; Ketamine; Methionine; Microplastics; Models, Animal; Plastics; Schizophrenia; Zebr | 2024 |
Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Anxiety; Depressive Disorder, Treatment-Resistant; Female; Humans; Inf | 2019 |
NMDA receptors and L-arginine/nitric oxide/cyclic guanosine monophosphate pathway contribute to the antidepressant-like effect of Yueju pill in mice.
Topics: Animals; Antidepressive Agents; Anxiety; Arginine; Cyclic GMP; Depression; Drugs, Chinese Herbal; Hi | 2019 |
Recovery of cognitive functioning following abstinence from ketamine.
Topics: Adult; Anxiety; Cognition; Cognitive Dysfunction; Depression; Excitatory Amino Acid Antagonists; Fem | 2019 |
Association of Craving and Depressive Symptoms in Ketamine-Dependent Patients Undergoing Withdrawal Treatment.
Topics: Adolescent; Adult; Anxiety; Behavior, Addictive; Craving; Depression; Female; Humans; Ketamine; Male | 2020 |
Sub-anesthetic and anesthetic ketamine produce different long-lasting behavioral phenotypes (24 h post-treatment) via inducing different brain-derived neurotrophic factor (BDNF) expression level in the hippocampus.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Behavior, Animal; Brain-Derived Neurot | 2020 |
A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: a retrospective pilot study.
Topics: Adult; Aged; Analysis of Variance; Anti-Anxiety Agents; Anxiety; Female; Humans; Ketamine; Male; Mid | 2020 |
Prenatal Exposure to Ketamine Leads to Anxiety-Like Behaviors and Dysfunction in Bed Nucleus of Stria Terminalis.
Topics: Age Factors; Anesthetics, Dissociative; Animals; Anxiety; Behavior, Animal; Disease Models, Animal; | 2020 |
Sexually Dimorphic Behavioral Profile in a Transgenic Model Enabling Targeted Recombination in Active Neurons in Response to Ketamine and (2R,6R)-Hydroxynorketamine Administration.
Topics: Animals; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cell Nucleus; Disease Models, | 2020 |
The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
Topics: Adult; Anxiety; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resista | 2020 |
Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.
Topics: Adult; Antidepressive Agents; Anxiety; Depressive Disorder, Treatment-Resistant; Female; Humans; Inf | 2021 |
Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale.
Topics: Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Double-Blind Method; Fear; Female; Humans; Ketamine | 2021 |
Neonatal exposure to ketamine disrupts developmental synapse unsilencing and predisposes adult mice for stressor-evoked anxiety.
Topics: Age Factors; Anesthetics, Dissociative; Animals; Animals, Newborn; Anxiety; Ketamine; Long-Term Pote | 2020 |
Facilitation of dopamine-dependent long-term potentiation in the medial prefrontal cortex of male rats follows the behavioral effects of stress.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Desipramine; Dopamine; Elevated Plus Maze Test; | 2021 |
No evidence for the effectiveness of IV ketamine for treatment resistant mood disorders in retrospective study.
Topics: Adult; Anxiety; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resista | 2020 |
The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
Topics: Administration, Intravenous; Adult; Anxiety; Anxiety Disorders; Bipolar Disorder; Canada; Depressive | 2021 |
Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity.
Topics: Adult; Antidepressive Agents; Anxiety; Anxiety Disorders; Comorbidity; Depression; Depressive Disord | 2021 |
Perspectives of Ketamine Use in COVID-19 Patients.
Topics: Anesthesia; Anxiety; COVID-19; COVID-19 Drug Treatment; Critical Care; Depression; Hemodynamics; Hos | 2021 |
Proteome profile of telencephalon associates attenuated neurogenesis with chronic stress induced mood disorder phenotypes in zebrafish model.
Topics: Affect; Animals; Antidepressive Agents; Anxiety; Cell Proliferation; Depression; Disease Models, Ani | 2021 |
Commentary on the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder.
Topics: Adult; Anxiety; Canada; Depressive Disorder, Major; Humans; Ketamine | 2021 |
Low doses of ketamine and guanosine abrogate corticosterone-induced anxiety-related behavior, but not disturbances in the hippocampal NLRP3 inflammasome pathway.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Guanosine; Hippocampus; Inflammasome | 2021 |
Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Anxiety; Behavior, Animal; Benzodiazepines; Do | 2017 |
Behavioral Changes in Children After Emergency Department Procedural Sedation.
Topics: Anesthetics, Dissociative; Anxiety; Chi-Square Distribution; Child; Child Behavior; Child, Preschool | 2018 |
The effects of ketamine on sexual behavior, anxiety, and locomotion in female rats.
Topics: Animals; Antidepressive Agents; Anxiety; Excitatory Amino Acid Antagonists; Female; Injections, Intr | 2018 |
Anxiolytic effects of ascorbic acid and ketamine in mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Ascorbic Acid; Behavior, Animal; Diazepam; Disease Models, An | 2018 |
Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalized Anxiety and Social Anxiety.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety; Brain; Dose-Response Relationship, Drug; Doub | 2018 |
Ambulatory colonoscopy under sedoanalgesia in adult patients with and without irritable bowel syndrome: A prospective, cross-sectional, and double-blind comparison.
Topics: Aged; Analgesia; Anxiety; Colonoscopy; Cross-Sectional Studies; Dose-Response Relationship, Drug; Do | 2018 |
Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzofurans; Citalopram; Depression; Depr | 2018 |
Single injection of ketamine during mid-adolescence promotes long-lasting resilience to activity-based anorexia of female mice by increasing food intake and attenuating hyperactivity as well as anxiety-like behavior.
Topics: Adolescent; Analgesics; Animals; Anorexia; Anxiety; Disease Models, Animal; Eating; Female; Humans; | 2018 |
Effects of Anesthetic Ketamine on Anxiety-Like Behaviour in Rats.
Topics: Anesthetics, Dissociative; Animals; Anxiety; Ketamine; Locomotion; Male; Photoperiod; Random Allocat | 2019 |
Ketamine improved depressive-like behaviors via hippocampal glucocorticoid receptor in chronic stress induced- susceptible mice.
Topics: Animals; Anxiety; Corticosterone; Depression; Depressive Disorder; Disease Models, Animal; Gene Expr | 2019 |
Comparison of the effects of 1MeTIQ and olanzapine on performance in the elevated plus maze test and monoamine metabolism in the brain after ketamine treatment.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Anxiety; Behavior, Animal; Brain; Dopamine; Dop | 2019 |
Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Biomarkers, Pharmacological; Depression; | 2019 |
Embryonic Ketamine Produces a Downregulation of Prefrontal Cortex NMDA Receptors and Anxiety-Like Behavior in Adult Offspring.
Topics: Animals; Anxiety; Down-Regulation; Excitatory Amino Acid Antagonists; Female; Hindlimb Suspension; H | 2019 |
The effects of sub-anesthetic ketamine plus ethanol on behaviors and apoptosis in the prefrontal cortex and hippocampus of adolescent rats.
Topics: Anesthetics, Dissociative; Animals; Anxiety; Apoptosis; bcl-2-Associated X Protein; Behavior, Animal | 2019 |
Chronic ketamine abuse is associated with orexin-A reduction and ACTH elevation.
Topics: Adrenocorticotropic Hormone; Adult; Anxiety; Case-Control Studies; Craving; Depressive Disorder; Fem | 2020 |
Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder.
Topics: Adult; Anxiety; Depressive Disorder, Major; Female; Humans; Ketamine; Middle Aged; Obsessive-Compuls | 2013 |
Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats.
Topics: Age Factors; Animals; Antidepressive Agents; Anxiety; Depression; Excitatory Amino Acid Antagonists; | 2013 |
Cognitive impairments in poly-drug ketamine users.
Topics: Anxiety; Case-Control Studies; Cognition Disorders; Depression; Excitatory Amino Acid Antagonists; E | 2013 |
Identification of a treatment-resistant, ketamine-sensitive genetic line in the chick anxiety-depression model.
Topics: Animals; Anxiety; Chickens; Depression; Disease Models, Animal; Ketamine | 2013 |
GABAA receptors containing ρ1 subunits contribute to in vivo effects of ethanol in mice.
Topics: Animals; Anxiety; Cells, Cultured; Central Nervous System Depressants; Ethanol; Female; GABA Agonist | 2014 |
Effects of single and combined gabapentin use in elevated plus maze and forced swimming tests.
Topics: Amines; Amitriptyline; Animals; Anticonvulsants; Anxiety; Cyclohexanecarboxylic Acids; Depression; D | 2014 |
Deletion of the Wolfram syndrome-related gene Wfs1 results in increased sensitivity to ethanol in female mice.
Topics: Animals; Anxiety; Central Nervous System Depressants; Dose-Response Relationship, Drug; Ethanol; Exp | 2015 |
Low-Dose Ketamine in Chronic Critical Illness.
Topics: Analgesics; Anxiety; Chronic Disease; Critical Care; Critical Illness; Dose-Response Relationship, D | 2016 |
Ketamine as a Prophylactic Against Stress-Induced Depressive-like Behavior.
Topics: Animals; Antidepressive Agents; Anxiety; Corticosterone; Depression; Fear; Helplessness, Learned; Ke | 2016 |
The positive effect on ketamine as a priming adjuvant in antidepressant treatment.
Topics: Animals; Antidepressive Agents; Anxiety; Aspartic Acid; Behavior, Animal; Brain; Depression; Depress | 2015 |
Ketamine induces anxiolytic effects in adult zebrafish: A multivariate statistics approach.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Dose-Response Relationship, Drug; Female; K | 2015 |
Oxytocin reduces amygdala activity, increases social interactions, and reduces anxiety-like behavior irrespective of NMDAR antagonism.
Topics: Amygdala; Animals; Anxiety; Brain Waves; Disease Models, Animal; Electroencephalography; Excitatory | 2015 |
Behavioral, endocrine, and neuronal alterations in zebrafish (Danio rerio) following sub-chronic coadministration of fluoxetine and ketamine.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Brain; Depression; Dis | 2015 |
Brain study seeks roots of suicide.
Topics: Anxiety; Biomarkers; Brain; Case-Control Studies; Depression; Humans; Ketamine; Risk Assessment; Ser | 2015 |
The nitric oxide donor sodium nitroprusside attenuates recognition memory deficits and social withdrawal produced by the NMDA receptor antagonist ketamine and induces anxiolytic-like behaviour in rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Excitatory Amino Acid Antagonists; Ketamine | 2016 |
Profiling the psychotic, depressive and anxiety symptoms in chronic ketamine users.
Topics: Adolescent; Adult; Anxiety; China; Comorbidity; Depression; Excitatory Amino Acid Antagonists; Femal | 2016 |
Rapamycin blocks the antidepressant effect of ketamine in task-dependent manner.
Topics: Animals; Antidepressive Agents; Anxiety; Avoidance Learning; Brain-Derived Neurotrophic Factor; Hipp | 2016 |
Repeated ketamine treatment induces sex-specific behavioral and neurochemical effects in mice.
Topics: Animals; Antidepressive Agents; Anxiety; Aspartic Acid; Depression; Female; Glutamic Acid; Hippocamp | 2016 |
Reactive Oxygen Species-mediated Loss of Phenotype of Parvalbumin Interneurons Contributes to Long-term Cognitive Impairments After Repeated Neonatal Ketamine Exposures.
Topics: Acetophenones; Animals; Anxiety; Brain; Cognitive Dysfunction; Cohort Studies; Disease Models, Anima | 2016 |
Behavioral alterations of zebrafish larvae after early embryonic exposure to ketamine.
Topics: Animals; Anxiety; Avoidance Learning; Behavior, Animal; Excitatory Amino Acid Antagonists; Ketamine; | 2017 |
Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Disease | 2009 |
Propofol/alfentanil and propofol/ketamine procedural sedation in children with acute lymphoblastic leukaemia: safety, efficacy and their correlation with pain neuromediator expression.
Topics: Adolescent; Alfentanil; Anxiety; Child; Child, Preschool; Conscious Sedation; Cross-Over Studies; Dr | 2010 |
Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care.
Topics: Administration, Oral; Aged; Analgesics; Antidepressive Agents; Anxiety; Depressive Disorder; Dose-Re | 2010 |
Ketamine reduces neuronal degeneration and anxiety levels when administered during early life-induced status epilepticus in rats.
Topics: Animals; Anxiety; Brain; Convulsants; Ketamine; Male; Nerve Degeneration; Neuroprotective Agents; Pi | 2012 |
Opposite effects of ethanol and ketamine in the elevated plus-maze test in Wistar rats undergoing a chronic oral voluntary consumption procedure.
Topics: Animals; Anxiety; Behavior, Animal; Central Nervous System Depressants; Ethanol; Excitatory Amino Ac | 2002 |
Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring.
Topics: Acoustic Stimulation; Animals; Animals, Newborn; Antipsychotic Agents; Antiviral Agents; Anxiety; Be | 2003 |
Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia.
Topics: Anesthetics, Dissociative; Animals; Anxiety; Disease Models, Animal; Injections, Intraperitoneal; Ke | 2003 |
Behavioral effects of ketamine and toxic interactions with psychostimulants.
Topics: Animals; Anxiety; Behavior, Animal; Central Nervous System Stimulants; Cocaine; Depression; Dose-Res | 2006 |
Substance use and related problems: a study on the abuse of recreational and not recreational drugs in Northern Italy.
Topics: Accidents, Traffic; Adult; Alcoholism; Amphetamines; Anxiety; Crack Cocaine; Depression; Female; Hal | 2006 |
Premedication for outpatient adenoidectomy: comparison between ketamine and pethidine.
Topics: Adenoidectomy; Ambulatory Surgical Procedures; Anesthesia, Inhalation; Anxiety; Child, Preschool; Ev | 1980 |
Midazolam with ketamine: who benefits?
Topics: Adjuvants, Anesthesia; Anesthesia Recovery Period; Anesthetics, Dissociative; Anti-Anxiety Agents; A | 2000 |
Ketamine abusers presenting to the emergency department: a case series.
Topics: Akathisia, Drug-Induced; Anesthetics, Dissociative; Anxiety; Chest Pain; Connecticut; Diagnosis, Dif | 2000 |
Effects of ketamine on different types of anxiety/fear and related memory in rats with lesions of the median raphe nucleus.
Topics: Analysis of Variance; Animals; Anxiety; Behavior, Animal; Fear; Ketamine; Male; Memory; Raphe Nuclei | 2001 |
Effects of ketamine on patient responsiveness during the various phases of a single induced anxiety session.
Topics: Adolescent; Adult; Anxiety; Arousal; Female; Humans; Ketamine; Male; Psychotherapy; Relaxation Thera | 1977 |
Ketamine-facilitated induced anxiety therapy and its effect upon clients' reactions to stressful situations.
Topics: Adaptation, Psychological; Adolescent; Adult; Affect; Anxiety; Arousal; Depression; Female; Humans; | 1979 |
Untoward effects of ketamine combined with diazepam for supplementing conduction anaesthesia in young and middle-aged adults.
Topics: Adult; Age Factors; Anesthesia, Conduction; Anesthesia, Epidural; Anxiety; Confusion; Diazepam; Dose | 1978 |
The dental treatment of problem children under ketamine analgesia.
Topics: Adolescent; Analgesia; Anesthesia, Dental; Anxiety; Child; Child, Preschool; Hemophilia A; Humans; I | 1975 |
Ketamine sedation for pediatric procedures: Part 1, A prospective series.
Topics: Adolescent; Anxiety; Child; Child, Preschool; Drug Evaluation; Emergency Medicine; Female; Humans; H | 1990 |
[Control of pain and anxiety in pedodontics].
Topics: Anesthesia, Dental; Anxiety; Child; Child, Preschool; Diazepam; Humans; Hydroxyzine; Ketamine; Nitro | 1989 |
Letter: Preoperative excitement and malignant hyperthermia.
Topics: Adult; Anesthesia, General; Anxiety; Child; Humans; Injections, Intramuscular; Ketamine; Male; Malig | 1974 |
Effect of thiopentone on emergence reactions to ketamine anaesthesia.
Topics: Anesthesia, Intravenous; Anxiety; Dreams; Female; Humans; Infusions, Parenteral; Ketamine; Thiopenta | 1974 |
A comparison of psychologic responses to ketamine and thiopental--nitrous oxide--halothane anesthesia.
Topics: Adult; Anesthetics; Anxiety; Attitude; Consciousness; Cyclohexanes; Drug Combinations; Halothane; Hu | 1972 |
Forearm blood flow during ketamine anaesthesia.
Topics: Adult; Anesthesia, Inhalation; Anesthesia, Intravenous; Anxiety; Auscultation; Blood Pressure; Dilat | 1972 |
[Avoiding of unpleasant postnarcotic dreams and anxiety with motoric restlessness following dissociation anesthesia with ketamine].
Topics: Adolescent; Adult; Analgesics; Anxiety; Benperidol; Cyclohexanes; Dreams; Drug Antagonism; Humans; K | 1971 |